

(12) STANDARD PATENT

(11) Application No. AU 2002337277 B2

(19) AUSTRALIAN PATENT OFFICE

(54) Title
Compositions for the treatment of Parkinson's disease containing CB1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain

(51) International Patent Classification(s)
A61K 45/00 (2006.01) **A61K 45/06** (2006.01)
A61K 31/198 (2006.01) **A61P 25/00** (2006.01)
A61K 31/397 (2006.01) **A61P 25/16** (2006.01)
A61K 31/4353 (2006.01) **A61P 43/00** (2006.01)
A61K 31/4427 (2006.01)

(21) Application No: **2002337277** (22) Date of Filing: **2002.08.28**

(87) WIPO No: **WO03/020314**

(30) Priority Data

(31) Number (32) Date (33) Country
01/11200 **2001.08.29** **FR**

(43) Publication Date: **2003.03.18**
(43) Publication Journal Date: **2003.06.05**
(44) Accepted Journal Date: **2008.06.05**

(71) Applicant(s)
Aventis Pharma S.A.

(72) Inventor(s)
Piot-Grosjean, Odile;Henin, Yvette;Benavides, Jesus;Boccio, Daniel

(74) Agent / Attorney
Watermark Patent & Trademark Attorneys, Level 2 302 Burwood Road, Hawthorn, VIC, 3122

(56) Related Art
British Journal of Pharmacology, 1998, 123, suppl 66P
FASEB Journal, 2000, 4(10), 1432-8

**(12) DEMANDE INTERNATIONALE PUBLIÉE EN VERTU DU TRAITÉ DE COOPÉRATION
EN MATIÈRE DE BREVETS (PCT)**

**(19) Organisation Mondiale de la Propriété
Intellectuelle**
Bureau international



(43) Date de la publication internationale
13 mars 2003 (13.03.2003)

PCT

(10) Numéro de publication internationale
WO 03/020314 A1

(51) Classification internationale des brevets⁷ :
A61K 45/06, A61P 25/16

(74) Mandataire : ROUSSEAU, Pierrick; Aventis Pharma S.A., Direction Brevets, 20, avenue Raymond Aron, F-92165 Antony Cedex (FR).

(21) Numéro de la demande internationale :
PCT/FR02/02946

(22) Date de dépôt international : 28 août 2002 (28.08.2002)

(25) Langue de dépôt : français

(26) Langue de publication : français

(81) États désignés (national) : AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(30) Données relatives à la priorité :
01/11200 29 août 2001 (29.08.2001) FR

(84) États désignés (régional) : brevet ARIPO (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), brevet eurasien (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), brevet européen (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), brevet OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Déposant (pour tous les États désignés sauf US) : AVEN-TIS PHARMA S.A. [FR/FR]; 20, avenue Raymond Aron, F-92160 Antony (FR).

Publiée :

— *avec rapport de recherche internationale*

En ce qui concerne les codes à deux lettres et autres abréviations, se référer aux "Notes explicatives relatives aux codes et abréviations" figurant au début de chaque numéro ordinaire de la Gazette du PCT.

(72) Inventeurs; et

(75) Inventeurs/Déposants (pour US seulement) : BENA-VIDES, Jésus [FR/FR]; 47, avenue de Seine, F-92500 Rueil-Malmaison (FR). BOCCIO, Daniel [FR/FR]; 27, rue Lourdeau, F-77310 Pringy (FR). HENIN, Yvette [FR/FR]; 12, rue Duchefdelaville, F-75013 Paris (FR). PIOT-GROSJEAN, Odile [FR/FR]; 12, rue Guy Moquet, F-94600 Choisy le Roi (FR).

(54) Title: COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE CONTAINING A CB1 RECEPTOR ANTAGONIST AND A PRODUCT THAT ACTIVATES DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN

(54) Titre : COMPOSITIONS POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON CONTENANT UN ANTAGONISTE DU RECEPTEUR CB1 ET UN PRODUIT QUI ACTIVE LA NEUROTRANSMISSION DOPAMINERGIQUE DANS LE CERVEAU

(57) Abstract: The invention relates to the association of one or more CB1 antagonist azetidine derivatives and one or more products that activate dopaminergic neurotransmission in the brain, the pharmaceutical compositions containing same and the use thereof for the treatment of Parkinson's disease.

(57) Abrégé : La présente invention concerne l'association d'un ou de plusieurs dérivés d'azétidine antagonistes CB1 et d'un ou de plusieurs produits qui activent la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de Parkinson.

WO 03/020314 A1

5 COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF A PRODUCT
WHICH ACTIVATES DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN,
THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR
USE IN THE TREATMENT OF PARKINSON'S DISEASE

10 The present invention relates to combination of one or more products
which activate dopaminergic neurotransmission in the brain and of one or more
azetidine derivatives chosen from the following compounds:

15 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-yl)

methylsulphonamide,

20 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)

methylsulphonamide,

their pharmaceutically acceptable salts,

25 to the pharmaceutical compositions comprising them and to their use in the
treatment of Parkinson's disease.

CB1 receptor antagonists have been developed for the treatment of schizophrenia (D. Kendall, Curr. Opin. Cent. Peripher. Nerv. Syst. Invest. Drugs, 2(1), 112-122, 2000), for their effect on food intake (G. Colombo et al., Life Sciences, 63 (8), 113-117 (1998); J. Siamand et al., Behavioural Pharmacol., 9, 179-181 (1998)) and for the treatment of Parkinson's disease, epilepsy, migraine and stress (G. Gerdeman, DM. Lovinger, J. Neurophysiol., 85(1), 468-471, 2001; WO 0046209).

30 Parkinson's disease results from a chronic and progressive neurological disorder. It is based on a deficiency of dopamine and a relative excess of acetylcholine and is associated with destruction of the dopaminergic neurones which participate in the control of the motor activities (H. Lullmann et al., *Atlas de poche de pharmacologie* [Pocket atlas of pharmacology], 2nd Ed., Médecine-Sciences, Flammarion, ISBN2-257-12119-8). The treatment of Parkinson's disease is mainly pharmacological and involves various medicaments intended to increase the amount of dopamine present in the brain.

As dopamine does not pass through the hematoencephalic barrier, levodopa, a precursor of dopamine converted to dopamine by dopa decarboxylase, was developed in the 1960s. Levodopa remains today the

first treatment of choice for Parkinson's disease and initially gives good results. However, after several years, fluctuations in response (on-off effect), a decrease in its effectiveness as the disease progresses

5 (wearing-off effect) and in particular dyskinesias (involuntary abnormal movements) are observed in the majority of patients. A psychotic state may also be observed.

Other medicaments, such as dopaminergic

10 agonists, are also recommended, alone or in combination with levodopa, and have as main aim that of reducing, at least, the undesirable effects of the latter. For some years, selective inhibitors of monoamine oxidase MAO-B, an enzyme which decomposes dopamine in the

15 brain, and inhibitors of catechol-O-methyltransferase (COMT), an enzyme which prevents levodopa from crossing the hematoencephalic barrier, have been developed and prescribed in combination with levodopa. Significant side effects have also been observed with these

20 therapies.

In order to overcome the abovementioned disadvantages, it has been found that the combination of one or more CB1 receptor antagonists and of one or more products which activate dopaminergic

25 neurotransmission in the brain has a synergistic effect in the treatment of Parkinson's disease. This is because this combination would make it possible to potentiate the symptomatic effects of a dopaminergic monotherapy (levodopa, dopaminergic agonists and enzyme

30 inhibitors) and would make it possible to reduce the side effects, in particular dyskinesias.

In addition to levodopa, a precursor of dopamine, mention may be made, among dopaminergic agonists, of the following products: bromocriptine

35 (Novartis), cabergoline (Pharmacia Corp.), adrogolide (Abbott Laboratories), BAM-1110 (Maruko Seiyaku Co. Ltd), Duodopa® (Neopharma), L-dopa, dopadose

(Neopharma), CHF1512 (Chiesi), NeuroCell-PD (Diacrin Inc.), PNU-95666 (Pharmacia & Upjohn), ropinirole (GlaxoSmithKline Beecham), pramipexole (Boehringer Ingelheim), rotigotine (Discovery Therapeutics, Lohmann Therapy System), spheramine (Titan Pharmaceuticals), TV1203 (Teva Pharmaceutical) or uridine (Polifarma).

Mention may be made, among MAO_B inhibitors, of: rasagiline (Teva Pharmaceutical Ind.), selegiline (RPScherer Corp./Elan) or SL340026 (Sanofi-Synthelabo).

Mention may be made, among COMT inhibitors, of: tolcapone (Roche) and entacapone (Orion Pharma).

A subject-matter of the invention is therefore the combination of one or more products which activate dopaminergic neurotransmission in the brain and of one or more azetidine derivatives chosen from the following compounds:

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-yl)


15 methylsulphonamide,

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)

methylsulphonamide,

their pharmaceutically acceptable salts.

Use may in particular be made, among CB1 antagonists, of the azetidine derivatives disclosed in patent applications FR 0002775, FR 0002777 and FR 0002776 of formula (I):



in which

25 either A:

R represents a CR₁R₂, C=C(R₅)SO₂R₆ or C=C(R₇)SO₂alk radical, either R₁ represents a hydrogen atom and R₂ represents a -C(R₈)(R₉)(R₁₀), -C(R₈)(R₁₁)(R₁₂), -CO-NR₁₃R₁₄, -CH₂-CO-NR₁₃R₁₄, -CH₂-CO-R₆, -CO-R₆, -CO-cycloalkyl, -SO-R₆, -SO₂-R₆, -C(OH)(R₁₂)(R₆), -C(OH)(R₆)(alkyl), -C(=NOalk)R₆, -C(=NO-CH₂-CH=CH₂)R₆, -CH₂-CH(R₆)NR₃₁R₃₂,

$-\text{CH}_2-\text{C}(=\text{NOalk})\text{R}_6$, $-\text{CH}(\text{R}_6)\text{NR}_{31}\text{R}_{32}$, $-\text{CH}(\text{R}_6)\text{NHSO}_2\text{alk}$,
 $-\text{CH}(\text{R}_6)\text{NHCONHalk}$ or $-\text{CH}(\text{R}_6)\text{NHCOalk}$ radical,

or R_1 represents an alkyl, NH-R_{15} , cyano,

$-\text{S-alk-NR}_{16}\text{R}_{17}$, $-\text{CH}_2-\text{NR}_{18}\text{R}_{19}$ or $-\text{NR}_{20}\text{R}_{21}$ radical and R_2

5 represents a $-\text{C}(\text{R}_8)(\text{R}_{11})(\text{R}_{12})$ radical,

R_3 and R_4 , which are identical or different, represent either an alkyl or cycloalkyl radical, or an aromatic radical chosen from phenyl, naphthyl or indenyl, these aromatic radicals being unsubstituted or

10 substituted by one or more halogen, alkyl, alkoxy, formyl, hydroxyl, trifluoromethyl, trifluoromethoxy, $-\text{CO-alk}$, cyano, $-\text{COOH}$, $-\text{COOalk}$, $-\text{CONR}_{22}\text{R}_{23}$, $-\text{CO-NH-NR}_{24}\text{R}_{25}$, alkylsulphanyl, alkylsulphinyl, alkylsulphonyl, alkylsulphonylalkyl, alkylsulphinyl-15 alkyl, alkylsulphonylalkyl, hydroxyalkyl or $-\text{alk-NR}_{24}\text{R}_{25}$; or a heteroaromatic radical chosen from the benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, 2,3-dihydroxybenzofuryl, 2,3-dihydrobenzothienyl, furyl, imidazolyl, isochromanyl, isoquinolyl, pyrrolyl, 20 pyridyl, pyrimidinyl, quinolyl, 1,2,3,4-tetrahydroisoquinolyl, thiazolyl and thienyl rings, it being possible for these heteroaromatic radicals to be unsubstituted or substituted by one or more halogen, alkyl, alkoxy, hydroxyl, trifluoromethyl,

25 trifluoromethoxy, cyano, $-\text{COOH}$, $-\text{COOalk}$, $-\text{CO-NH-NR}_{24}\text{R}_{25}$, $-\text{CONR}_{22}\text{R}_{23}$, $-\text{alk-NR}_{24}\text{R}_{25}$, alkylsulphanyl, alkylsulphinyl, alkylsulphonyl, alkylsulphonylalkyl, alkylsulphinyl-alkyl, alkylsulphonylalkyl or hydroxyalkyl,

R_5 represents a hydrogen atom or an alkyl

30 radical,

R_6 represents an Ar_1 or Het_1 radical,

R_7 represents a cycloalkyl, heterocycloalkyl or heterocyclenyl radical optionally substituted by a $-\text{CSO-phenyl}$ radical,

35 R_8 represents a hydrogen atom or an alkyl radical,

R₉ represents a -CO-NR₂₆R₂₇, -COOH, -COOalk, -CH₂OH, -NH-CO-NH-alk, -CH₂-NHR₂₈ or -NHCOOalk radical,

R₁₀ represents an Ar₁ or Het₁ radical,

R₁₁ represents an -SO₂-alk, -SO₂-Ar₁ or

5 -SO₂-Het₁ radical,

R₁₂ represents a hydrogen atom or an Ar₁ or Het₁ radical,

R₁₃ represents a hydrogen atom or an alkyl radical,

10 R₁₄ represents an Ar₁, Het₁, -alk-Ar₁ or -alk-Het₁ radical,

R₁₅ represents an alkyl, cycloalkyl or -alk-NR₂₉R₃₀ radical,

15 R₁₆ and R₁₇, which are identical or different, represent a hydrogen atom or an alkyl radical or else R₁₆ and R₁₇ form, together with the nitrogen atom to which they are attached, a saturated or unsaturated and mono- or bicyclic heterocycle having 3 to 10 ring members and optionally comprising one or more other 20 heteroatoms chosen from oxygen, sulphur and nitrogen and optionally substituted by one or more alkyl radicals,

R₁₈ represents a hydrogen atom or an alkyl radical,

25 R₁₉ represents a hydrogen atom or an alkyl, cycloalkyl, cycloalkylalkyl, cycloalkylcarbonyl, -SO₂alk, -CO-NHalk or -COOalk radical,

30 or else, R₁₈ and R₁₉ form, with the nitrogen atom to which they are attached, a saturated or unsaturated and mono- or bicyclic heterocycle having 3 to 10 ring members and optionally comprising one or more heteroatoms chosen from oxygen, sulphur and nitrogen and optionally substituted by one or more alkyl radicals,

35 -NR₂₀R₂₁ represents a saturated or unsaturated monocyclic heterocycle having 3 to 8 ring members and

optionally comprising another heteroatom chosen from oxygen, nitrogen and sulphur,

R₂₂ and R₂₃, which are identical or different, represent a hydrogen atom or an alkyl radical or else

5 R₂₂ and R₂₃ form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulphur and nitrogen and optionally being substituted

10 by one more alkyl radicals,

R₂₄ and R₂₅, which are identical or different, represent a hydrogen atom or an alkyl, -COOalk, cycloalkyl, alkylcycloalkyl, -alk-O-alk or hydroxyalkyl radical or else R₂₄ and R₂₅ form, together with the

15 nitrogen atom to which they are attached, a saturated or unsaturated and mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulphur and nitrogen and optionally being substituted by one or more alkyl,

20 -COalk, -COOalk, -CO-NHalk, -CS-NHalk, oxo, hydroxyalkyl, -alk-O-alk or -CO-NH₂ radicals,

R₂₆ and R₂₇, which are identical or different, represent a hydrogen atom or an alkyl, hydroxyalkyl, cycloalkyl, cycloalkylalkyl, -alk-COOalk, -alk-Ar₁,

25 alk-Het₁, Het₁ or -alk-N(alk)₂ radical, R₂₆ and R₂₇ can also form, with the nitrogen atom to which they are attached, a saturated or unsaturated and mono- or bicyclic heterocycle having 3 to 10 ring members and optionally comprising one or more heteroatoms chosen

30 from oxygen, sulphur and nitrogen and optionally substituted by one or more alkyl, alkoxy or halogen radicals,

R₂₈ represents a -CH₂-alk, benzyl, -SO₂alk, -CONHalk, -COalk, cycloalkylalkylcarbonyl,

35 cycloalkylcarbonyl or -CO-(CH₂)_nOH radical,
n is equal to 1, 2, or 3,

R_{29} and R_{30} , which are identical or different, represent a hydrogen atom or an alkyl radical or else R_{29} and R_{30} form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic 5 heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulphur and nitrogen and optionally being substituted by one or more alkyl radicals,

R_{31} and R_{32} , which are identical or different, 10 represent a hydrogen atom or an alkyl, Ar_1 or -alk- Ar_1 radical or else R_{31} and R_{32} form, together with the nitrogen atom to which they are attached, a heterocycle chosen from aziridinyl, azetidinyl, pyrrolidinyl and piperidinyl,

15 Ar_1 represents a phenyl or naphthyl radical optionally substituted by one or more substituents chosen from halogen, alkyl, alkoxy, -CO-alk, cyano, -COOH, -COOalk, -CONR₂₂R₂₃, -CO-NH-NR₂₄R₂₅, alkylsulphonyl, alkylsulphanyl, alkylsulphinyl, 20 alkylsulphanylalkyl, alkylsulphinylalkyl, alkylsulphonylalkyl, hydroxyalkyl, -alk-NR₂₄R₂₅, -NR₂₄R₂₅, alkylthioalkyl, formyl, hydroxyl, CF₃, OCF₃, Het₁, O-alk-NH-cycloalkyl or SO₂NH₂,

25 Het₁ represents a saturated or unsaturated and mono- or bicyclic heterocycle having 3 to 10 ring members and comprising one or more heteroatoms chosen from oxygen, sulphur and nitrogen and optionally substituted by one or more halogen, alkyl, alkoxy, alkoxy carbonyl, -CONR₂₂R₂₃, hydroxyl, hydroxyalkyl, oxo 30 or SO₂NH₂,

or B:

R represents a CHR₃₃ radical,

35 R₃₃ represents an -NHCOR₃₄ or -N(R₃₅)-Y-R₃₆ radical,

Y is CO or SO₂,

R₃ and R₄, which are identical or different, represent either an aromatic radical chosen from

phenyl, naphthyl and indenyl, these aromatic radicals being unsubstituted or substituted by one or more halogen, alkyl, alkoxy, formyl, hydroxyl, trifluoromethyl, trifluoromethoxy, -CO-alk, cyano,

5 -COOH, -COOalk, -CONR₃₇R₃₈, -CO-NH-NR₃₉R₄₀, alkylsulphanyl, alkylsulphinyl, alkylsulphonyl, alkylsulphanylalkyl, alkylsulphinylalkyl, alkylsulphonylalkyl, hydroxyalkyl or -alk-NR₃₇R₃₈; or a heteroaromatic radical chosen from the benzofuryl,

10 benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, 2,3-dihydrobenzofuryl, 2,3-dihydrobenzothienyl, pyrimidinyl, furyl, imidazolyl, isochromanyl, isoquinolyl, pyrrolyl, pyridyl, quinolyl, 1,2,3,4-tetrahydroisoquinolyl, thiazolyl and thienyl rings, it

15 being possible for these heteroaromatic radicals to be unsubstituted or substituted by a halogen, alkyl, alkoxy, hydroxyl, trifluoromethyl, trifluoromethoxy, cyano, -COOH, -COOalk, -CO-NH-NR₃₉R₄₀, -CONR₃₇R₃₈, -alk-NR₃₉R₄₀, alkylsulphanyl, alkylsulphinyl, alkylsulphonyl,

20 alkylsulphanylalkyl, alkylsulphinylalkyl, alkylsulphonylalkyl or hydroxyalkyl,

R₃₄ represents an -alk-SO₂-R₄₁ radical, an -alk-SO₂-CH=CH-R₄₁ radical, a Het₂ radical substituted by -SO₂-R₄₁ or a phenyl radical substituted by -SO₂-R₄₁ or

25 -alk-SO₂-R₄₁,

R₃₅ represents a hydrogen atom or an alkyl radical,

R₃₆ represents a phenylalkyl, Het₂ or Ar₂ radical,

30 R₃₇ and R₃₈, which are identical or different, represent a hydrogen atom or an alkyl radical or else R₃₇ and R₃₈ form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally

35 comprising another heteroatom chosen from oxygen, sulphur and nitrogen and optionally being substituted by one or more alkyl,

R_{39} and R_{40} , which are identical or different, represent a hydrogen atom or an alkyl, $-COOalk$, $cycloalkyl$, $alkylcycloalkyl$, $-alk-O-alk$ or $hydroxyalkyl$ radical or else R_{39} and R_{40} form, together with the

5 nitrogen atom to which they are attached, a saturated or unsaturated and mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulphur and nitrogen and optionally being substituted by one or more alkyl,

10 $-COOalk$, $-COOalk$, $-CO-NHalk$, $-CS-NHalk$, oxo, $hydroxyalkyl$, $-alk-O-alk$ or $-CO-NH_2$,

R_{41} represents an alkyl, Ar_2 or Het_2 radical,

Ar_2 represents a phenyl, naphthyl or indenyl radical, these radicals optionally being substituted by

15 one or more halogen, alkyl, alkoxy, cyano, $-CO-alk$, $-COOH$, $-COOalk$, $-CONR_{42}R_{43}$, $-CO-NH-NR_{44}R_{45}$, $alkylsulphanyl$, $alkylsulphinyl$, $alkylsulphonyl$, $-alk-NR_{44}R_{45}$, $-NR_{44}R_{45}$, $alkythioalkyl$, formyl, hydroxyl, hydroxyalkyl, Het_2 , $-O-alk-NH-cycloalkyl$, OCF_3 , CF_3 ,

20 $-NH-CO-alk$, $-SO_2NH_2$, $-HN-COCH_3$, $-NH-COOalk$ or Het_2 or else on two adjacent carbon atoms by a dioxymethylene,

Het_2 represents a saturated or unsaturated and mono- or bicyclic heterocycle having 3 to 10 ring members and comprising one or more heteroatoms chosen

25 from oxygen, sulphur and nitrogen optionally substituted by one or more alkyl, alkoxy, vinyl, halogen, alkoxy carbonyl, oxo, hydroxyl, OCF_3 or CF_3 , the nitrogenous heterocycles optionally being in their N-oxidized form,

30 R_{42} and R_{43} , which are identical or different, represent a hydrogen atom or an alkyl radical or else R_{42} and R_{43} form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulphur and nitrogen and optionally being substituted by one or more alkyl radicals,

35

R_{44} and R_{45} , which are identical or different, represent a hydrogen atom or an alkyl, $-COOalk$, cycloalkyl, alkylcycloalkyl, $-alk-O-alk$ or hydroxyalkyl radical or else R_{44} and R_{45} form, together with the 5 nitrogen atom to which they are attached, a saturated or unsaturated and mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulphur and nitrogen and optionally being substituted by one or more alkyl, 10 $-COOalk$, $-COOalk$, $-CO-NHalk$, $-CS-NHalk$, oxo, hydroxyalkyl, $-alk-O-alk$ or $-CO-NH_2$ radicals, 15 or C:

R represents a CHR_{46} radical,

R_{46} represents an $-N(R_{47})R_{48}$, $-N(R_{47})-CO-R_{48}$ or 15 $-N(R_{47})-SO_2R_{49}$ radical,

R_3 and R_4 , which are identical or different, represent either an aromatic radical chosen from phenyl, naphthyl and indenyl, these aromatic radicals being unsubstituted or substituted by one or more 20 halogen, alkyl, alkoxy, formyl, hydroxyl, trifluoromethyl, trifluoromethoxy, $-CO-alk$, cyano, $-COOH$, $-COOalk$, $-CONR_{50}R_{51}$, $-CO-NH-NR_{52}R_{53}$, alkylsulphanyl, alkylsulphinyl, alkylsulphonyl, alkylsulphanylalkyl, alkylsulphinylalkyl, 25 alkylsulphonylalkyl, hydroxyalkyl or $-alk-NR_7R_8$ radicals; or a heteroaromatic radical chosen from the benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, 2,3-dihydrobenzofuryl, 2,3-dihydrobenzothienyl, furyl, imidazolyl, isochromanyl, 30 isoquinolyl, pyrrolyl, pyridyl, pyrimidyl, quinolyl, 1,2,3,4-tetrahydroisoquinolyl, thiazolyl and thieryl rings, it being possible for these heteroaromatic radicals to be unsubstituted or substituted by a halogen, alkyl, alkoxy, hydroxyl, trifluoromethyl, 35 trifluoromethoxy, cyano, $-COOH$, $-COOalk$, $-CO-NH-NR_{52}R_{53}$, $-CONR_{50}R_{51}$, $-alk-NR_{52}R_{53}$, alkylsulphanyl, alkylsulphinyl, alkylsulphonyl, alkylsulphanylalkyl,

alkylsulphanylalkyl, alkysulphonylalkyl or hydroxyalkyl radical,

R₄₇ represents a -C(R₅₄)(R₅₅)-Het₃, -Het₃, -C(R₅₄)(R₅₅)-Ar₃, Ar₃, cycloalkyl or norbornyl radical,

5 R₄₈ represents a hydrogen atom or a hydroxyalkyl radical, -alk-COOalk radical, -alk-CONR₅₀R₅₁ radical, -alk-NR₅₀R₅₁ radical, alkoxy radical, Ar₃ radical, Het₃ radical, -CH₂Ar₃ radical, -CH₂Het₃ radical or alkyl radical optionally substituted with one or

10 more halogen,

R₄₉ represents a hydroxyalkyl radical, -alk-COOalk radical, -alk-CONR₅₀R₅₁ radical, -alk-NR₅₀R₅₁ radical, alkoxy radical, Ar₃ radical, Het₃ radical, -CH₂Ar₃ radical, -CH₂Het₃ radical or alkyl radical

15 optionally substituted with one or more halogen,

R₅₀ and R₅₁, which are identical or different, represent a hydrogen atom or an alkyl radical or else R₅₀ and R₅₁ form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulphur and nitrogen and optionally being substituted by one or more alkyl,

20 R₅₂ and R₅₃, which are identical or different, represent a hydrogen atom or an alkyl, -COOalk, cycloalkyl, alkylcycloalkyl, -alk-O-alk or hydroxyalkyl radical or else R₅₂ and R₅₃ form, together with the nitrogen atom to which they are attached, a saturated or unsaturated and mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulphur and nitrogen and optionally being substituted by one or more alkyl, -COalk, -COOalk, -CO-NHalk, -CS-NHalk, oxo, hydroxyalkyl, -alk-O-alk or -CO-NH₂,

25 R₅₄ represents a hydrogen atom or a hydroxyalkyl radical, -alk-COOalk radical, -alk-CONR₅₀R₅₁ radical, -alk-NR₅₀R₅₁ radical, alkoxyalkyl radical, Ar₃

radical, Het_3 radical, $-\text{CH}_2\text{Ar}_3$ radical, $-\text{CH}_2\text{Het}_3$ radical or alkyl radical optionally substituted with one or more halogen,

R_{55} represents a hydrogen atom or a

5 hydroxyalkyl radical, $-\text{alk}-\text{COOalk}$ radical, $-\text{alk}-\text{CONR}_{50}\text{R}_{51}$ radical, $-\text{alk}-\text{NR}_{50}\text{R}_{51}$ radical, alkoxyalkyl radical or alkyl radical optionally substituted with one or more halogen,

or else R_{54} and R_{55} form, together with the

10 carbon atom to which they are attached, a saturated mono- or bicyclic ring having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulphur and nitrogen and optionally being substituted by one or more alkyl,

15 Ar_3 represents a phenyl, naphthyl or indenyl radical, these various radicals optionally being substituted by one or more halogen, alkyl, alkoxy, $-\text{CO-alk}$, cyano, $-\text{COOH}$, $-\text{COOalk}$, $-\text{CONR}_{56}\text{R}_{57}$, $-\text{CO-NH-NR}_{58}\text{R}_{59}$, alkylsulphonyl, alkylsulphanyl, alkylsulphanyl, 20 $-\text{alk-NR}_{58}\text{R}_{59}$, $-\text{NR}_{58}\text{R}_{59}$, alkylthioalkyl, formyl, CF_3 , OCF_3 , Het_3 , $-\text{O-alk-NH-cycloalkyl}$, SO_2NH_2 , hydroxyl, hydroxyalkyl, $-\text{NHCOalk}$ or $-\text{NHCOOalk}$ or on 2 adjacent carbon atoms by dioxymethylene,

25 Het_3 represents a saturated or unsaturated and mono- or bicyclic heterocycle having 3 to 10 ring members and comprising one or more heteroatoms chosen from oxygen, sulphur and nitrogen optionally substituted by one or more alkyl, alkoxy, halogen, alkoxy carbonyl, oxo or hydroxyl, the nitrogenous 30 heterocycles optionally being in their N-oxidized form,

35 R_{56} and R_{57} , which are identical or different, represent a hydrogen atom or an alkyl radical or else R_{56} and R_{57} form, together with the nitrogen atom to which they attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen,

sulphur and nitrogen and optionally being substituted by one or more alkyl,

R_{58} and R_{59} , which are identical or different, represent a hydrogen atom or an alkyl radical or else

5 R_{58} and R_{59} form, together with the nitrogen atom to which they are attached, a saturated mono- or bicyclic heterocycle having 3 to 10 ring members optionally comprising another heteroatom chosen from oxygen, sulphur and nitrogen and optionally being substituted
10 by one or more alkyl,

alk represents an alkyl or alkylene radical,

the alkyl and alkylene radicals and portions and the alkoxy radicals and portions have straight or branched chains and comprise 1 to 6 carbon atoms, the
15 cycloalkyl radicals comprise 3 to 10 carbon atoms and the heterocycloalkyl and heterocyclenyl radicals comprise 3 to 10 carbon atoms,

the optical isomers of these compounds and their pharmaceutically acceptable salts with an
20 inorganic or organic acid.

Mention may be made, among preferred azetidine derivatives which are a subject-matter of the present invention, of the following derivatives:

(RS)-1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluoro-
25 phenyl)(methylsulphonyl)methyl]azetidine,
(R)-1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluoro-phenyl)(methylsulphonyl)methyl]azetidine,
(S)-1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluoro-phenyl)(methylsulphonyl)methyl]azetidine,
30 (RS)-1-[bis(4-chlorophenyl)methyl]-3-[(pyrid-3-yl)-(methylsulphonyl)methyl]azetidine,
(R)-1-[bis(4-chlorophenyl)methyl]-3-[(pyrid-3-yl)-(methylsulphonyl)methyl]azetidine,
(S)-1-[bis(4-chlorophenyl)methyl]-3-[(pyrid-3-yl)-(methylsulphonyl)methyl]azetidine,
35 (RS)-1-[bis(3-fluorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulphonyl)methyl]azetidine,

(R)-1-[bis(3-fluorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulphonyl)methyl]azetidine,
 (S)-1-[bis(3-fluorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulphonyl)methyl]azetidine,
 5 1-[bis(4-chlorophenyl)methyl]-3-(RS)-{[3-(azetidin-1-yl)phenyl](methylsulphonyl)methyl}azetidine,
 1-[bis(4-chlorophenyl)methyl]-3-(R)-{[3-(azetidin-1-yl)phenyl](methylsulphonyl)methyl}azetidine,
 1-[bis(4-chlorophenyl)methyl]-3-(S)-{[3-(azetidin-1-yl)phenyl](methylsulphonyl)methyl}azetidine,
 10 1-[bis(4-chlorophenyl)methyl]-3-[(RS)-{[3-(azetidin-1-yl)phenyl](methylsulphonyl)methyl}azetidine,
 (RS)-1-[3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}(methylsulphonyl)methyl]pyrrolidine,
 (R)-1-[3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}(methylsulphonyl)methyl]pyrrolidine,
 15 (S)-1-[3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}(methylsulphonyl)methyl]pyrrolidine,
 (RS)-N-[3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}(methylsulphonyl)methyl]phenyl]-N-methylamine,
 (R)-N-[3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}(methylsulphonyl)methyl]phenyl]-N-methylamine,
 20 3-[(methylsulphonyl)methyl]phenyl]-N-methylamine,
 (S)-N-[3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}(methylsulphonyl)methyl]phenyl]-N-methylamine,
 (RS)-1-[bis(4-chlorophenyl)methyl]-3-[(3,5-bis(trifluoromethyl)phenyl)(methylsulphonyl)methyl]azetidine,
 25 (R)-1-[bis(4-chlorophenyl)methyl]-3-[(3,5-bis(trifluoromethyl)phenyl)(methylsulphonyl)methyl]azetidine,
 (S)-1-[bis(4-chlorophenyl)methyl]-3-[(3,5-bis(trifluoromethyl)phenyl)(methylsulphonyl)methyl]azetidine,
 1-[bis(4-chlorophenyl)methyl]-3-(phenylsulphonyl)-
 30 methyl]azetidine,
 (RS)-1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulphonyl)methyl]-3-methylazetidine,
 (R)-1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulphonyl)methyl]-3-methylazetidine,
 35 (S)-1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulphonyl)methyl]-3-methylazetidine,

(RS)-2-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-
2-(3,5-difluorophenyl)-N-cyclohexylacetamide,
(R)-2-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-
2-(3,5-difluorophenyl)-N-cyclohexylacetamide,
5 (S)-2-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-
2-(3,5-difluorophenyl)-N-cyclohexylacetamide,
(RS)-2-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-
2-(3,5-difluorophenyl)-N-isobutylacetamide,
(R)-2-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-
10 2-(3,5-difluorophenyl)-N-isobutylacetamide,
(S)-2-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-
2-(3,5-difluorophenyl)-N-isobutylacetamide,
(RS)-2-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-
2-(3,5-difluorophenyl)-N-cyclopropylmethylacetamide,
15 (R)-2-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-
2-(3,5-difluorophenyl)-N-isopropylacetamide,
(S)-2-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-
2-(3,5-difluorophenyl)-N-cyclopropylmethylacetamide,
(RS)-2-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-
20 2-(3,5-difluorophenyl)-N-isopropylacetamide,
(R)-2-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-
2-(3,5-difluorophenyl)-N-isopropylacetamide,
(S)-2-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-
2-(3,5-difluorophenyl)-N-isopropylacetamide,
25 (RS)-1-[bis(4-chlorophenyl)methyl]-3-[1-(3,5-difluoro-
phenyl)-1-(methylsulphonyl)ethyl]azetidine,
(R)-1-[bis(4-chlorophenyl)methyl]-3-[1-(3,5-difluoro-
phenyl)-1-(methylsulphonyl)ethyl]azetidine,
(S)-1-[bis(4-chlorophenyl)methyl]-3-[1-(3,5-difluoro-
30 phenyl)-1-(methylsulphonyl)ethyl]azetidine,
(RS)-1-[bis(4-fluorophenyl)methyl]-3-[(3,5-difluoro-
phenyl)(methylsulphonyl)methyl]azetidine,
(R)-1-[bis(4-fluorophenyl)methyl]-3-[(3,5-difluoro-
phenyl)(methylsulphonyl)methyl]azetidine,
35 (S)-1-[bis(4-fluorophenyl)methyl]-3-[(3,5-difluoro-
phenyl)(methylsulphonyl)methyl]azetidine,

(RS)-{1-[(3-pyridyl)(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulphonyl)methyl]azetidine,
 (SS)-{1-[(3-pyridyl)(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulphonyl)methyl]azetidine,
 5 (RR)-{1-[(3-pyridyl)(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulphonyl)methyl]azetidine,
 (SR)-{1-[(3-pyridyl)(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulphonyl)methyl]azetidine,
 (RS)-{1-[(4-pyridyl)(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulphonyl)methyl]azetidine,
 10 (SS)-{1-[(4-pyridyl)(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulphonyl)methyl]azetidine,
 (RR)-{1-[(4-pyridyl)(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulphonyl)methyl]azetidine,
 15 (SR)-{1-[(4-pyridyl)(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulphonyl)methyl]azetidine,
 (RS)-5-((4-chlorophenyl){3-[(3,5-difluorophenyl)-(methylsulphonyl)methyl]azetidin-1-yl)methyl)-pyrimidine,
 20 (SR)-5-((4-chlorophenyl){3-[(3,5-difluorophenyl)-(methylsulphonyl)methyl]azetidin-1-yl)methyl)-pyrimidine,
 (RR)-5-((4-chlorophenyl){3-[(3,5-difluorophenyl)-(methylsulphonyl)methyl]azetidin-1-yl)methyl)-
 25 pyrimidine,
 (SS)-5-((4-chlorophenyl){3-[(3,5-difluorophenyl)-(methylsulphonyl)methyl]azetidin-1-yl)methyl)-pyrimidine,
 (SS)-{1-[(2-chloropyrid-5-yl)(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulphonyl)methyl]azetidine,
 30 (RR)-{1-[(2-chloropyrid-5-yl)(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulphonyl)methyl]azetidine,
 (RS)-{1-[(2-chloropyrid-5-yl)(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulphonyl)methyl]azetidine,
 35 (SR)-{1-[(2-chloropyrid-5-yl)(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulphonyl)methyl]azetidine,

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}thien-2-ylsulfonamide,

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-4-methoxyphenylsulfonamide,

5 N-[4-(N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}sulphamoyl)phenyl]acetamide,

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-4-methylphenylsulphonamide,

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3,4-

10 dimethoxyphenylsulphonamide,

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3-fluorophenylsulphonamide,

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3,4-dichlorophenylsulphonamide,

15 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3-cyanophenylsulphonamide,

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-2,5-dimethoxyphenylsulphonamide,

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3-

20 trifluoromethylphenylsulphonamide,

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}naphth-2-ylsulphonamide,

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}naphth-1-ylsulphonamide,

25 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3,4-difluorophenylsulphonamide,

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-1-methyl-1*H*-imidazol-4-ylsulphonamide,

N-[4-(N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}sulphamoyl)-2-chlorophenyl]acetamide,

30 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}pyrid-3-ylsulphonamide,

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-4-fluorophenylsulphonamide,

35 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}quinol-8-ylsulphonamide,

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}phenylsulphonamide,

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}(phenylmethyl)sulphonamide,

5 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3,5-difluorophenylsulphonamide,

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}pyrid-2-ylsulphonamide,

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-(3-

10 fluoro-5-pyrrolidin-1-ylphenyl)sulphonamide,

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-methyl-4-fluorophenylsulphonamide,

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-methylquinol-8-ylsulphonamide,

15 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-methylphenylsulphonamide,

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-methyl(phenylmethyl)sulphonamide,

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3-

20 sulphamoylphenylsulphonamide,

2-benzenesulphonyl-N-{1-[bis(4-chlorophenyl)methyl]-azetidin-3-yl}acetamide,

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-2-(toluene-4-sulphonyl)acetamide,

25 (3-chloro-4-(methylsulphonyl)thiophene-2-carboxy)-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}amide,

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3-(2-phenylethylenesulphonyl)propionamide,

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-4-

30 (methylsulphonyl)benzamide,

(5-(methylsulphonyl)thiophene-2-carboxy)-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}amide,

(5-(methylsulphonyl)-3-methyl-4-vinylthiophene-2-carboxy)-{1-[bis(4-chlorophenyl)methyl]azetidin-3-

35 yl}amide,

(RS)-N-{1-[{4-chlorophenyl}(pyridin-3-yl)methyl]-azetidin-3-yl}-3,5-difluorobenzenesulphonamide,

(RS)-N-{1-[{4-chlorophenyl}(pyrimidin-5-yl)methyl]-azetidin-3-yl}-3,5-difluorobenzenesulphonamide,
N-{1-[bis{4-chlorophenyl}methyl]azetidin-3-yl}-N-(6-chloropyrid-2-yl)methylsulphonamide,
5 N-{1-[bis{4-chlorophenyl}methyl]azetidin-3-yl}-N-(6-ethylpyrid-2-yl)methylsulphonamide,
N-{1-[bis{4-chlorophenyl}methyl]azetidin-3-yl}-N-(quinol-6-yl)methylsulphonamide,
N-{1-[bis{4-chlorophenyl}methyl]azetidin-3-yl}-N-
10 (quinol-5-yl)methylsulphonamide,
N-{1-[bis{4-chlorophenyl}methyl]azetidin-3-yl}-N-(isoquinol-5-yl)methylsulphonamide,
N-{1-[bis{4-chlorophenyl}methyl]azetidin-3-yl}-N-(pyrid-3-yl)methylsulphonamide,
15 N-{1-[bis{4-chlorophenyl}methyl]azetidin-3-yl}-N-(1-oxidopyrid-3-yl)methylsulphonamide,
N-((1R,2S,4S)bicyclo[2.2.1]hept-2-yl)-N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}methylsulphonamide,
N-((1R,2R,4S)bicyclo[2.2.1]hept-2-yl)-N-{1-[bis(4-
20 chlorophenyl)methyl]azetidin-3-yl}methylsulphonamide,
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulphonamide,
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(thiazol-2-yl)methylsulphonamide,
25 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3-methoxyphenyl)methylsulphonamide,
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3-hydroxyphenyl)methylsulphonamide,
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3-
30 (hydroxymethyl)phenyl)methylsulphonamide,
ethyl N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(methylsulphonyl)-3-aminobenzoate
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(1-isobutylpiperid-4-yl)methylsulphonamide,
35 N-benzyl-N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}amine

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorobenzyl)amine,

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorobenzyl)methylsulphonamide,

5 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-ylmethyl)methylsulphonamide,

N-{1-[bis(4-fluorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulphonamide,

(RS)-N-{1-[(4-chlorophenyl)(pyrid-3-yl)methyl]azetidin-10 3-yl}-N-(3,5-difluorophenyl)methylsulphonamide,

(R)-N-{1-[(4-chlorophenyl)(pyrid-3-yl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulphonamide,

(S)-N-{1-[(4-chlorophenyl)(pyrid-3-yl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulphonamide,

15 (RS)-N-{1-[(4-chlorophenyl)(pyrid-4-yl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulphonamide,

(R)-N-{1-[(4-chlorophenyl)(pyrid-4-yl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulphonamide,

(S)-N-{1-[(4-chlorophenyl)(pyrid-4-yl)methyl]azetidin-20 3-yl}-N-(3,5-difluorophenyl)methylsulphonamide,

(RS)-N-{1-[(4-chlorophenyl)(pyrimidin-5-yl)methyl]-azetidin-3-yl}-N-(3,5-difluorophenyl)methyl-sulphonamide,

(R)-N-{1-[(4-chlorophenyl)(pyrimidin-5-yl)methyl]-25 azetidin-3-yl}-N-(3,5-difluorophenyl)methyl-sulphonamide,

(S)-N-{1-[(4-chlorophenyl)(pyrimidin-5-yl)methyl]-azetidin-3-yl}-N-(3,5-difluorophenyl)methyl-sulphonamide,

30 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)benzylsulphonamide,


their optical isomers and their pharmaceutically acceptable salts.

Mention may be made, as examples of 35 pharmaceutically acceptable salts of azetidine derivatives, of the following salts: benzenesulphonate, hydrobromide, hydrochloride, citrate, ethanesulphonate,

fumarate, gluconate, iodate, isethionate, maleate, methanesulphonate, methylenebis(oxynaphthoate), nitrate, oxalate, pamoate, phosphate, salicylate, succinate, sulphate, tartrate, theophyllineacetate and 5 p-toluenesulphonate.

The azetidine derivatives are synthesized according to the following general methods:

The compounds of formula (I) for which R represents the CR₁R₂ radical in which R₁ represents a 10 hydrogen atom and R₂ represents a C(R₈)(R₁₁)(R₁₂) radical in which R₈ represents a hydrogen atom, R₁₁ represents an -SO₂-Ar₁, -SO₂-Het₁ or -SO₂alk radical and R₁₂ represents a hydrogen atom or an Ar₁ or Het₁ radical and the compounds of formula (I) for which R represents a 15 C=C(R₅)SO₂R₆ or C=C(R₇)SO₂alk radical can be prepared according to the following reaction scheme:



In these formulae, either Ra represents an alkyl, Het_1 or Ar_1 radical and Rb represents a hydrogen atom or an Ar_1 or Het_1 radical; or Ra represents an Ar_1

or Het₁ radical and Rb represents a hydrogen atom or an alkyl radical; or Ra represents an alkyl radical and Rb represents a cycloalkyl, heterocycloalkyl or heterocyclenyl radical optionally substituted by a

5 -CSO-phenyl radical; and Rc represents a hydrogen atom or an acetyl radical; R₃, R₄, Ar₁ and Het₁ have the same meanings as in the formula (I).

The reactions d and e can only be used when Rb is a hydrogen atom.

10 The reaction a is generally carried out in an inert solvent, such as an ether (for example tetrahydrofuran), in the presence of a strong base, such as tert-butyllithium, n-butyllithium, lithium diisopropylamide or potassium tert-butoxide, at a

15 temperature of between -70°C and -15°C.

The dehydration reaction b is generally carried out by any dehydration method known to a person skilled in the art which makes it possible to dehydrate an alcohol to produce the corresponding alkene.

20 Preferably, the acetyloxy derivative is prepared by reaction with acetyl chloride in an inert solvent, such as pyridine, tetrahydrofuran, dioxane or a chlorinated solvent (for example dichloromethane or chloroform), at a temperature of between 5°C and 20°C, and then the

25 product is treated with a base, such as an alkali metal hydroxide (for example sodium hydroxide), an alkali metal carbonate (for example sodium carbonate or potassium carbonate) or an amine, such as a trialkylamine (for example triethylamine), 4-

30 dimethylaminopyridine or 1,8-diazabicyclo[5.4.0]undec-7-ene, at a temperature of between 0°C and the boiling temperature of the reaction medium. The intermediate acetyloxy may or may not be isolated. The acetyloxy can also be prepared directly in the reaction medium of

35 reaction a.

The reduction c is generally carried out in an inert solvent, such as a (1-4C) aliphatic alcohol

(for example methanol), a chlorinated solvent (for example chloroform or dichloromethane) or a mixture of these solvents, in the presence of NaBH_4 , at a temperature of between 0°C and the boiling temperature 5 of the reaction medium.

The reaction d is carried out by reaction with trimethylsilyl chloride in an inert solvent, such as an ether (for example tetrahydrofuran), in the presence of n-butyllithium, at a temperature of -70°C .

10 The reaction e is generally carried out in an inert solvent, such as an ether (for example tetrahydrofuran), in the presence of a strong base, such as tert-butyllithium, n-butyllithium, lithium diisopropylamide or potassium tert-butoxide, at a 15 temperature of between -70°C and -15°C .

The hydrolysis g is carried out in an inert solvent, such as an ether (for example dioxane), by means of hydrochloric acid at a temperature in the region of 20°C .

20 The reactions h and j are preferably carried out in an inert solvent, such as acetonitrile, in the presence of a base, such as an alkali metal carbonate (for example potassium carbonate), at the boiling temperature of the reaction medium.

25 The reaction i is carried out under a hydrogen atmosphere in the presence of a catalyst, such as palladium or one of its derivatives, in an inert solvent, such as methanol or ethanol, at a temperature of between 15°C and 60°C .

30 The reaction k is carried out in an inert solvent, such as a chlorinated solvent (for example dichloromethane or chloroform), at a temperature of between 0°C and the boiling temperature of the reaction mixture.


35 The $\text{R}_3\text{CH}(\text{Br})\text{R}_4$ derivatives are commercially available or can be obtained by application or adaptaton of the method described by Bachmann W.E., J.

Am. Chem. Soc., 2135 (1933). Generally, the corresponding alcohol R_3CHOHR_4 is brominated by means of hydrobromic acid in acetic acid at a temperature of between $0^\circ C$ and the boiling temperature of the reaction medium.

The corresponding alcohols R_3CHOHR_4 are commercially available or can be obtained by application or adaptation of the methods described by Plasz A.C. et al., J. Chem. Soc. Chem. Comm., 527 (1972).

The following intermediates can be obtained by application or adaptation of the methods described in the examples. The following reaction schemes in particular are used:

15



In these formulae, Hal represents a halogen atom and preferably chlorine, bromine or iodine.

The reaction is generally carried out in an inert solvent, such as dimethylformamide or a 1-4C aliphatic alcohol, at a temperature of between $20^\circ C$ and $30^\circ C$.

The reactions b and e are carried out by any known method which makes it possible to oxidise a

sulphur derivative without affecting the remainder of the molecule, such as those described by M. Hudlicky, *Oxidations in Organic Chemistry*, ACS Monograph, 186, 252-263 (1990). For example, the reaction is carried out by the action of an organic peroxyacid or a salt of such a peroxyacid (peroxycarboxylic or peroxy sulphonic acids, in particular peroxybenzoic acid, 3-chloroperoxybenzoic acid, 4-nitroperoxybenzoic acid, peroxyacetic acid, trifluoroperoxyacetic acid, peroxyformic acid or monoperoxyphthalic acid) or inorganic peracids or a salt of such an acid (for example periodic or persulphuric acid) in an inert solvent, such as a chlorinated solvent (for example chloroform and dichloromethane), at a temperature of between 0 and 25°C. Use may also be made of hydrogen peroxide, optionally in the presence of a metal oxide (sodium tungstate) or a periodate (for example sodium periodate), in an inert solvent, such as a 1-4C aliphatic alcohol (for example methanol or ethanol), acetic acid, water or a mixture of these solvents, at a temperature of between 0 and 60°C. It is also possible to carry out the reaction by means of tert-butyl hydroperoxide in the presence of titanium tetrakisopropylate in a 1-4C aliphatic alcohol (for example methanol or ethanol) or a water/alcohol mixture, at a temperature in the region of 25°C, or by means of oxone® (potassium peroxy monosulphate) in a 1-4C aliphatic alcohol (for example methanol or ethanol), in the presence of water, acetic acid or sulphuric acid, at a temperature in the region of 20°C.

The reaction c is preferably carried out in an inert solvent, such as a 1-4C aliphatic alcohol (for example methanol or ethanol), at a temperature of between 20°C and the boiling temperature of the reaction medium.


The reaction d is carried out under an inert atmosphere (argon) at a temperature of between 50°C and the boiling temperature of the reaction medium.

5 The reaction f is generally carried out in an inert solvent, such as tetrahydrofuran or an aliphatic ether (for example ethylether), at a temperature in the region of -70°C.

10 The reaction g is generally carried out in an inert solvent, such as dimethylformamide, an aliphatic ether (for example ethylether) or a 1-4 aliphatic alcohol, in the presence of a base (for example sodium hydride), at a temperature of between 0°C and 60°.

15 The derivatives of formula Rb-CH₂-Hal are commercially available or can be obtained by application or adaptation of the methods described in the examples. In particular, the corresponding methyl derivative or alcohol is halogenated by means of a halogenating agent, such as hydrobromic acid in acetic acid at a temperature in the region of 20°C or N-bromo-20 or N-chlorosuccinimide in the presence of benzoyl peroxide in an inert solvent, such as tetrachloromethane, at the boiling temperature of the reaction medium. The corresponding methyl derivatives or alcohols are commercially available or can be 25 obtained according to the methods described by Brine G.A. et al., J. Heterocycl. Chem., 26, 677 (1989), and Nagarathnam D., Synthesis, 8, 743 (1992), and in the examples.

30 The azetidinones of formula 3 can be obtained by application or adaptation of the methods described by Katritzky A.R. et al., J. Heterocycl. Chem., 271 (1994), or Dave P.R., J. Org. Chem., 61, 5453 (1996), and in the examples. The preparations are generally carried out according to the following reaction scheme:



In these formulae, R_3 and R_4 have the same meanings as in formula (I) and Hal represents a chlorine or bromine atom.

5 In stage A, the reaction is preferably carried out in an inert solvent, such as a 1-4C aliphatic alcohol (for example ethanol or methanol), optionally in the presence of an alkali metal hydroxide, at the boiling temperature of the reaction
10 medium.

In stage B, the reduction is generally carried out by means of lithium aluminium hydride in tetrahydrofuran at the boiling temperature of the reaction medium.

15 In stage C, the reaction is preferably carried out in an inert solvent, such as a 1-4C aliphatic alcohol (for example ethanol or methanol), in the presence of sodium hydrogencarbonate at a temperature of between 20°C and the boiling temperature
20 of the reaction medium.

In stage D, the oxidation is carried out preferably in DMSO by means of the sulphur trioxide-

pyridine complex at a temperature in the region of 20°C or by means of dimethyl sulphoxide, in the presence of oxalyl chloride and of triethylamine, at a temperature of between -70 and -50°C.

5 In stage E, the reaction is carried out according to the method described by Grisar M. et al., in J. Med. Chem., 885 (1973). The magnesium product of the bromine derivative is formed and then the nitrile is reacted in an ether, such as ethylether, at a
10 temperature of between 0°C and the boiling temperature of the reaction medium. After hydrolysis with an alcohol, the intermediate imine is reduced *in situ* with sodium borohydride at a temperature of between 0°C and the boiling temperature of the reaction medium.


15 The $R_3\text{-CO-R}_4$ derivatives are commercially available or can be obtained by application or adaptation of the methods described by Kunder N.G. et. al., J. Chem. Soc. Perkin Trans. 1, 2815 (1997); Moreno-Marras M., Eur. J. Med. Chem., 23 (5), 477 (1988); Skinner et al., J. Med. Chem., 14 (6), 546 (1971); Hurn N.K., Tet. Lett., 36 (52), 9453 (1995); Medici A. et al., Tet. Lett., 24 (28), 2901 (1983); Riecke R.D. et al., J. Org. Chem., 62 (20), 6921 (1997); Knabe J. et al., Arch. Pharm., 306 (9), 25 648 (1973); Consonni R. et al., J. Chem. Soc. Perkin Trans. 1, 1809 (1996); FR-96-2481 and JP-94-261393.

The $R_3\text{Br}$ derivatives are commercially available or can be obtained by application or adaptation of the methods described by Brandsma L. et al., Synth. Comm., 20 (11), 1697 and 3153 (1990); Lemaire M. et al., Synth. Comm., 24 (1), 95 (1994); Goda H. et al., Synthesis, 9, 849 (1992); and Baeuerle P. et al., J. Chem. Soc. Perki Trans. 2, 489 (1993).

35 The $R_4\text{CN}$ derivatives are commercially available or can be obtained by application or adaptation of the methods described by

Bouyssou P. et al., J. Het. Chem., 29 (4), 895 (1992);
Suzuki N. et al., J. Chem. Soc. Chem. Comm., 1523
(1984); Marburg S. et al., J. Het. Chem., 17, 1333
(1980); and Percec V. et al., J. Org. Chem., 60 (21),
5 6895 (1995).

The compounds of formula (I) for which R represents a CR_1R_2 radical in which R_1 represents a hydrogen atom and R_2 represents a $C(R_8)(R_9)(R_{10})$ radical in which R_8 represents a hydrogen atom, R_9 represents a
10 $-CO-NR_{26}R_{27}$, $-COOH$, $-COOalk$, $-CH_2OH$, $-NHCOOalk$ or $-NH-CO-$
 $NH-alk$ radical and R_{10} represents an Ar_1 or Het_1 radical can be prepared according to the following reaction scheme:



In these formulae, R_3 , R_4 , R_{10} , R_{26} and R_{27} have the same meanings as in the formula (I) and alk 5 represents an alkyl radical.

The derivatives of formula 4 are commercially available or can be obtained by esterification of the corresponding acids optionally in an activated form, such as the acid chloride. The acids are commercially

available or can be obtained from the corresponding methyl derivatives according to the method described by J.P. Hansen et al., J. Heterocycl., 10, 711 (1973).

5 The reaction a is generally carried out in an inert solvent, such as an ether (for example tetrahydrofuran), in the presence of a strong base, such a tert-butyllithium, n-butyllithium, lithium diisopropylamide or potassium tert-butoxide, at a temperature of between -70°C and -15°C.

10 The reaction b is generally carried out by any dehydration method known to a person skilled in the art which makes it possible to dehydrate an alcohol to produce the corresponding alkene and in particular the methods described above.

15 The reduction c is generally carried out in an inert solvent, such as a (1-4C) aliphatic alcohol, such as methanol, a chlorinated solvent, such as a chloroform or dichloromethane, or a mixture of these solvents, in the presence of NaBH₄ at a temperature of 20 between 0°C and the boiling temperature of the reaction medium.

The reaction d is carried out by any method known to a person skilled in the art which makes it possible to convert an ester to the corresponding acid 25 without effecting the remainder of the molecule. The reaction is preferably carried out in an inert solvent, such as dioxane, in the presence of hydrochloric acid at the boiling temperature of the reaction medium.


The reaction e is carried out by any method 30 known to a person skilled in the art which makes it possible to convert an acid or a reactive derivative of this acid to a carboxamide without affecting the remainder of the molecule. Preferably, when the acid is employed, the reaction is carried out in the presence 35 of a coupling agent used in peptide chemistry, such as a carbodiimide (for example N,N'-dicyclohexylcarbodiimide) or N,N'-carbonyldiimidazole, in an inert

solvent, such as an ether (for example tetrahydrofuran or dioxane), an amide (dimethylformamide) or a chlorinated solvent (for example methylene chloride, 1,2-dichloroethane or chloroform), at a temperature of
 5 between 0°C and the reflux temperature of the reaction mixture. When a reactive derivative of the acid is employed, it is possible to react the anhydride, a mixed anhydride or an ester (which can be chosen from activated or nonactivated esters of the acid); the
 10 reaction is then carried out either in an organic medium, optionally in the presence of an acid acceptor, such as a nitrogenous organic base (for example trialkylamine, pyridine, 1,8-diazabicyclo[5.4.0]undec-7-ene or 1,5-diazabicyclo[4.3.0]non-5-ene), in a
 15 solvent such as is mentioned above or a mixture of these solvents, at a temperature of between 0°C and the reflux temperature of the reaction mixture, or in a two-phase aqueous/organic medium in the presence of an alkali metal or alkaline earth metal base (sodium
 20 hydroxide, potassium hydroxide) or of an alkali metal carbonate or bicarbonate or alkaline earth metal carbonate or bicarbonate at a temperature between 0 and 40°C.

The reaction f is carried out by the Curtius
 25 rearrangement in the presence of diphenylphosphoryl azide and the triethylamine in toluene at a temperature in the region of 50°C.

For the reactions g and h, the reaction is carried out directly in the reaction medium of stage g
 30 at a temperature in the region of 20°C.

The compounds of formula (I) for which R represents the CR₁R₂ radical in which R₁ is a hydrogen atom and R₂ represents a -C(R₈)(R₉)(R₁₀) radical for which R₈ is a hydrogen atom, R₉ is an -CH₂-NHR₂₈ radical
 35 and R₁₀ represents an Ar₁ or Het₁ radical can be prepared according to the following reaction scheme:



In these formulae, R_3 , R_4 and R_{10} have the same meanings as in the formula (I), Rd represents an alkyl or phenyl radical, Re represents an alkyl radical, Rf represents an alkyl radical, Rg represents an alkyl, cycloalkylalkyl, cycloalkyl or $-(CH_2)_nOH$ radical and n is equal to 1, 2 or 3.


The stage a is generally carried out in an inert solvent, such as a (1-4C) aliphatic alcohol (for example methanol), a chlorinated solvent (for example dichloromethane or dichloroethane) or tetrahydrofuran, in the presence of a base, such as $NaBH(OCOCH_3)_3$, at a temperature in the region of $20^\circ C$.

The stage b is generally carried out in an inert solvent, such as a halogenated solvent (for example dichloromethane), in the presence of an organic base, such as triethylamine or dimethylaminopyridine, at a temperature of between $0^\circ C$ and the boiling temperature of the reaction medium.

The stage c is generally carried out in an inert solvent, such as tetrahydrofuran, dimethylformamide, a chlorinated solvent (for example chloroform or 1,2-dichloroethane) or an aromatic solvent (for example benzene or toluene), at a temperature of between 10°C and the boiling temperature of the reaction medium.

The stage d is carried out by any method known to a person skilled in the art which makes it possible to convert an acid or a reactive derivative of this acid to a carboxamide without affecting the remainder of the molecule and in particular the preferred methods described above.

The derivative 6 can be obtained according to the following reaction scheme:




In these formulae, R_3 , R_4 and R_{10} have the same meanings as in the formula (I) and Ms is a methylsulphonyloxy radical.

The stage a is generally carried out in an inert solvent, such as tetrahydrofuran, in the presence of triethylamine at a temperature of between 10 and 20°C.

The stage b is generally carried out with liquid ammonia in methanol, in an autoclave, at a temperature in the region of 60°C.

5 The compounds of formula (I) in which R represents a CR_1R_2 radical in which R_1 is a hydrogen atom and R_2 is a $-\text{CONR}_{13}\text{R}_{14}$ radical can be prepared according to the following reaction scheme:



10 In these formulae, R_3 , R_4 , R_{13} and R_{14} have the same meanings as the formula (I), Ms represents a methylsulphonyloxy radical and Et represents ethyl.

15 The stage a is carried out in the presence of triethylamine in an inert solvent, such as an ether (for example tetrahydrofuran), at a temperature in the region of 0°.

The stage b is generally carried out in an inert solvent, such as a mixture of water and dimethylformamide, at a temperature of between 30 and 75°C.

20 The stage c is carried out by any method known to a person skilled in the art which makes it possible to convert a cyano compound to the corresponding acid without affecting the remainder of the molecule. The reaction is preferably carried out by 25 means of potassium hydroxide in a (1-4C) aliphatic


alcohol (for example ethanol) or in aqueous medium at the boiling temperature of the reaction medium.

The stage d is carried out by any method known to a person skilled in the art which makes it

5 possible to convert an acid or a reactive derivative of this acid to a carboxamide without affecting the remainder of the molecule molecule and in particular the preferred methods described above.

The compounds of formula (I) for which R

10 represents a CR_1R_2 radical in which R_1 is a hydrogen atom and R_2 is a $-CH_2-CONR_{13}R_{14}$ radical can be prepared according to the following reaction scheme:



15 In these formulae, R_3 , R_4 , R_{13} and R_{14} have the same meanings as in the formula (I) and Et represents an ethyl radical.

The reaction a is generally carried out in an inert solvent, such as tetrahydrofuran, in the presence

20 of a base, such as sodium hydride or an alkali metal carbonate (for example potassium carbonate), at a temperature between 20°C and the boiling temperature of the reaction medium.


The reaction b is generally carried out by

25 means of $NaBH_4$ in ethanol at a temperature in the region of 0°C.

The reaction c is carried out by any method known to a person skilled in the art which makes it possible to convert an ester to the corresponding acid without affecting the remainder of the molecule. The 5 reaction is preferably carried out in an inert solvent, such as dioxane, in the presence of hydrochloric acid at the boiling temperature of the reaction medium.

The reaction d is carried out by any method known to a person skilled in the art which makes it 10 possible to convert an acid or a reactive derivative of this acid to a carboxamide without affecting the remainder of the molecule and in particular the preferred methods described above.

The intermediates 7 can also be obtained by 15 malonic synthesis according to the following reaction scheme:




20 In these formulae, Ms represents a methylsulphonyloxy radical and R₃ and R₄ have the same meanings as in the formula (I).

The reaction a is generally carried out by reaction with diethyl malonate in an inert solvent, 25 such as tetrahydrofuran, in the presence of freshly prepared sodium ethoxide at the boiling temperature of the reaction medium.

The reaction b is generally carried out in an aqueous hydrochloric acid solution at the boiling 30 temperature of the reaction medium.

The compounds 8 can also be obtained according to the following reaction scheme:




5 In these formulae, R_3 , R_4 , R_{13} and R_{14} have the same meanings as in the formula (I).

Stage a is carried out by any method known to a method known to a person skilled in the art which makes it possible to convert an acid or a reactive 10 derivative of this acid to a carboxamide without affecting the remainder of the molecule molecule and in particular the preferred methods described above.

Stage b is generally carried out in an inert solvent, such as tetrahydrofuran, in the presence of a 15 base, such as sodium hydride or potassium carbonate, at a temperature of between 20°C and the boiling temperature of the reaction mixture.

The reduction of stage c is generally carried out by means of NaBH_4 in ethanol at a temperature in the 20 region of 20°C .

The compounds of formula (I) for which R represents a CR_1R_2 radical in which R_1 is a hydrogen atom and R_2 represents an $-\text{SOR}_6$ or $-\text{SO}_2\text{R}_6$ radical can be prepared according to the following reaction scheme:



In these formulae, R_3 , R_4 and R_6 have the same meanings as in the formula (I) and Ms is a 5 methylsulphonyloxy radical.


Stage a is generally carried out in an inert solvent, such as tetrahydrofuran, in the presence of an inorganic base, such as sodium hydride, at a temperature of between 0°C and the boiling temperature 10 of the reaction medium.

Stage b is generally carried out by any method of a person skilled in the art for the oxidation of a sulphur derivative, such as those described by M. Hudlicky, *Oxidations in Organic Chemistry*, ACS 15 Monograph, 186, 252-263 (1990). For example, the reaction is carried out by the action of an organic peroxyacid or a salt of such an peroxyacid (peroxycarboxylic or peroxy sulphonic acids, in particular peroxybenzoic acid, 3-chloroperoxybenzoic 20 acid, 4-nitroperoxybenzoic acid, peroxyacetic acid, trifluoroperoxyacetic acid, peroxyformic acid or monoperoxyphthalic acid) or inorganic peracids or a salt of such an acid (for example periodic or persulphuric acid) in an inert solvent, such as a 25 chlorinated solvent (for example chloroform or dichloromethane), at a temperature of between 0 and

25°C or else by means of oxone in a water/alcohol (methanol, ethanol) mixture.

Stage c is generally carried out by any method of a person skilled in the art for the oxidation 5 of a sulphanyl derivative. Preferably, the reaction is carried out by the action of an organic peroxyacid or a salt of such a peroxyacid (peroxycarboxylic or peroxy sulphonic acids, in particular peroxybenzoic acid, 3-chloroperoxybenzoic acid, 4-nitroperoxybenzoic 10 acid, peroxyacetic acid, trifluoroperoxyacetic acid, peroxyformic acid or monoperoxyphthalic acid) or else by means of oxone in a water/alcohol (methanol, ethanol) mixture.

The compounds of formula (I) for which R 15 represents a CR_1R_2 radical in which R_1 is a hydrogen atom and R_2 represents a $-COR_6$ or $-CO$ -cycloalkyl radical can be prepared according to the following reaction scheme:




20

In these formulae, R_3 and R_4 have the same meanings as in the formula (I) and Rh has the same 25 meanings as R_6 or represents a cycloalkyl radical (3 to 10 carbon atoms).

Stage a is carried out by any method known to a person skilled in the art which makes it possible to convert an acid or a reactive derivative of this acid to a carboxamide without affecting the remainder of the 5 molecule molecule and in particular the preferred methods described above.

Stage b is generally carried out in an inert solvent, such as an ether, for example tetrahydrofuran, at a temperature in the region of 0°C. The 10 organomagnesium compounds are prepared according to methods known to a person skilled in the art, such as those described in the examples.

The compounds of formula (I) for which R_1 is a hydrogen atom and R_2 is a $-C(OH)(R_6)(R_{12})$, 15 $-C(OH)(R_6)(alkyl)$, $-C(=NO-CH_2-CH=CH_2)R_6$ or $-C(=NOalk)R_6$ radical can be prepared according to the following reaction scheme:




In these formulae, R₃, R₄ and R₆ have the same meanings as in the formula (I), R_i has the same meanings as R₁₂ or represents an alkyl radical (1 to 6 carbon atoms in a straight or branched chain) and R_j

represents an alkyl radical (1 to 6 carbon atoms in a straight or branched chain) or a $-\text{CH}_2\text{-CH=CH}_2$ radical.

Stage a is generally carried out in an inert solvent, such as an aliphatic alcohol (for example 5 ethanol), in the presence of sodium acetate at a temperature of between 20°C and the boiling temperature of the reaction medium.

Stage b is generally carried out in an inert solvent, such as an ether, for example tetrahydrofuran, 10 at a temperature in the region of 0°C. The organomagnesium compounds are prepared according to methods known to a person skilled in the art, such as those described in the examples.

The compounds of formula (I) for which R 15 represents a CR_1R_2 radical in which R_1 is a hydrogen atom and R_2 represents a $-\text{CH}(\text{R}_6)\text{NR}_{31}\text{R}_{32}$, in which R_{31} and R_{32} are hydrogen atoms, $-\text{CH}(\text{R}_6)\text{NHSO}_2\text{alk}$, $-\text{CH}(\text{R}_6)\text{NHCONHalk}$ or $-\text{CH}(\text{R}_6)\text{NHCOR}_{31}$ radical can be prepared according to the following reaction scheme:



In these formulae, R_3 , R_4 , R_6 and R_{31} have the same meanings as in the formula (I), Ms represents a 5 methylsulphonyloxy radical and alk represents an alkyl radical.

The reaction a is generally carried out by means of $NaBH_4$ in ethanol at a temperature in the region of $20^\circ C$.

Stage b is carried out in the presence of triethylamine in an inert solvent, such as an ether (for example tetrahydrofuran), at a temperature in the region of 0°C.

5 Stage c is carried out by means of liquid ammonia in methanol, in an autoclave, at a temperature in the region of 60°.

10 Stage d is generally carried out in an inert solvent, such as a halogenated solvent (for example dichloromethane) or tetrahydrofuran, in the presence of an organic base, such as triethylamine or dimethylaminopyridine, at a temperature in the region of 20°C.

15 Stage e is carried out by any method known to a person skilled in the art which makes it possible to convert an acid or a reactive derivative of this acid to a carboxamide without affecting the remainder of the molecule and in particular the preferred methods described above.

20 Stage f is generally carried out in an inert solvent, such as tetrahydrofuran, dimethylformamide, a chlorinated solvent (for example chloroform or dichloroethane) or an aromatic solvent (for example benzene or toluene), at a temperature of between 10°C
25 and the boiling temperature of the reaction medium.

The compounds of formula (I) for which R represents a CR_1R_2 radical in which R_1 is a hydrogen atom and R_2 represents a $-CH(R_6)NR_{31}R_{32}$ radical, R_{31} is a hydrogen atom and R_{32} is an alkyl, Ar_1 or $-alk-Ar_1$ 30 radical can be prepared by reaction of a halide $HalR_{31}$ with a compound of formula (I) for which R represents a CR_1R_2 radical in which R_1 is a hydrogen atom and R_2 represents a $-CH(R_6)NR_{31}R_{32}$ radical and R_{31} and R_{32} are hydrogen atoms.

35 This reaction is carried out in an inert polar solvent, such as acetonitrile, tetrahydrofuran or dimethylformamide, in the presence of an organic or

inorganic base (alkali metal carbonate (for example sodium or potassium carbonate) or trialkylamine (for example triethylamine or dimethylaminopyridine)) at a temperature of between 0°C and the boiling temperature 5 of the solvent, optionally in the presence of palladium or of one of its salts or complexes.

The compounds of formula (I) for which R represents a CR_1R_2 radical in which R_1 is a hydrogen atom and R_2 represents a $-CH(R_6)NR_{31}R_{32}$ radical, R_{31} is a 10 hydrogen atom and R_{32} is an alkyl radical can also be prepared by reaction of a corresponding compound of formula (I) for which R represents a CR_1R_2 radical in which R_1 is a hydrogen atom and R_2 represents a $-CO-R_6$ radical with an amine $HNR_{31}R_{32}$ for which R_{31} is a 15 hydrogen atom and R_{32} is an alkyl radical.

This reaction is generally carried out in an inert solvent, such as a chlorinated solvent (for example dichloromethane or dichloroethane), in the presence of a reducing agent, such as sodium 20 triacetoxyborohydride, at a temperature of between 0°C and 70°C.

The compounds of formula (I) for which R represents a CR_1R_2 radical in which R_1 is a hydrogen atom and R_2 represents a $-CH(R_6)NR_{31}R_{32}$ radical and R_{31} 25 and R_{32} are alkyl, Ar_1 or $-alk-Ar_1$ radicals can be prepared by reaction of a halide $HalR_{32}$ with a compound of formula (I) for which R represents a CR_1R_2 radical in which R_1 is a hydrogen atom and R_2 represents a $-CH(R_6)NR_{31}R_{32}$ radical, R_{31} is a hydrogen atom and R_{32} is 30 an alkyl, Ar_1 or $-alk-Ar_1$ radical.

This reaction is carried out in an inert polar solvent, such as acetonitrile, tetrahydrofuran or dimethylformamide, in the presence of an organic or inorganic base (alkali metal carbonate (for example 35 sodium or potassium carbonate) or trialkylamine (for example triethylamine or dimethylaminopyridine)) at a temperature of between 0°C and the boiling temperature

of the solvent, optionally in the presence of palladium or of one of its salts or complexes.

The compounds of formula (I) for which R represents a CR_1R_2 radical in which R_1 is a hydrogen atom and R_2 represents a $-CH(R_6)NR_{31}R_{32}$ radical, R_{31} is a hydrogen atom and R_{32} is a (2-6C) alkyl or -(2-6C)alkyl- Ar_1 radical can be prepared by reaction of an aldehyde $RaCHO$ for which Ra is an alkyl or -alk- Ar_1 radical with a compound of formula (I) for which R represents a CR_1R_2 radical in which R_1 is a hydrogen atom and R_2 represents a $-CH(R_6)NR_{31}R_{32}$ radical and R_{31} and R_{32} are hydrogen atoms.

This reaction is carried out in an inert solvent, such as dichloromethane, dichloroethane, toluene or tetrahydrofuran, at a temperature of between 0°C and 50°C in the presence of a reducing agent, such as sodium triacetoxyborohydride or sodium cyanoborohydride.

The compounds of formula (I) for which R represents a CR_1R_2 radical in which R_1 is a hydrogen atom and R_2 represents a $-CH(R_6)NR_{31}R_{32}$ radical, R_{31} is an alkyl, Ar_1 or -alk- Ar_1 radical and R_{32} is a (2-6C) alkyl or -(2-6C)alkyl- Ar_1 radical can be prepared by reaction of an aldehyde $RaCHO$ for which Ra is an alkyl or alk- Ar_1 radical with a compound of formula (I) for which R represents a CR_1R_2 radical in which R_1 is a hydrogen atom and R_2 represents a $-CH(R_6)NR_{31}R_{32}$ radical, R_{31} is a hydrogen atom and R_{32} is an alkyl, Ar_1 or -alk- Ar_1 radical.

This reaction is carried out in an inert solvent, such as dichloromethane, dichloroethane, toluene or tetrahydrofuran, at a temperature of between 0°C and 50°C in the presence of a reducing agent, such as sodium triacetoxyborohydride or sodium cyanoborohydride.


The compounds of formula (I) for which R represents a CR_1R_2 radical in which R_1 is a hydrogen

atom and R₂ represents a -CH(R₆)NR₃₁R₃₂ radical and R₃₁ and R₃₂ form, with the nitrogen atom to which they are attached, a heterocycle chosen from aziridinyl, azetidinyl, pyrrolidinyl or piperidinyl, can be

5 prepared by reaction of a dihalide Hal-(2-5C)alk-Hal with a compound of formula (I) for which R represents a CR₁R₂ radical in which R₁ is a hydrogen atom and R₂ represents a -CH(R₆)NR₃₁R₃₂ radical and R₃₁ and R₃₂ are hydrogen atoms.

10 This reaction is carried out in an inert polar solvent, such as acetonitrile, tetrahydrofuran or dimethylformamide, in the presence of an organic or inorganic base (alkali metal carbonate (for example sodium or potassium carbonate) or trialkylamine (for example triethylamine or dimethylaminopyridine)) at a temperature of between 0°C and the boiling temperature of the solvent, optionally in the presence of palladium or of one of its salts or complexes.

15 The compounds of formula (I) for which R represents a CR₁R₂ radical in which R₁ is a hydrogen atom and R₂ represents a -CH₂-COR₆, -CH₂-CH(R₆)NR₃₁R₃₂ or -CH₂-C(=NOalk)R₆ radical can be prepared according to the following reaction scheme:



In these formulae, R_3 , R_4 , R_6 , R_{31} and R_{32} have the same meaning as in the formula (I) and alk 5 represents an alkyl radical.

Stage a is generally carried out in a solvent, such as tetrahydrofuran, at a temperature of between 20°C and the boiling temperature of the reaction medium.

10 Stage b is generally carried out in an inert solvent, such as an aliphatic alcohol (for example methanol), a chlorinated solvent (chloroform,

dichloromethane) or a mixture of these solvents, in the presence of a reducing agent, such as NaBH_4 , at a temperature of between 0°C and the boiling temperature of the reaction medium.


5 Stage c is carried out by any method known to a person skilled in the art which makes it possible to convert an acid or a reactive derivative of this acid to a carboxamide without affecting the remainder of the molecule and in particular the preferred methods
10 described above.

Stage d is generally carried out in an inert solvent, such as an ether, for example tetrahydrofuran, at a temperature in the region of 0°C . The organomagnesium compounds are prepared according to
15 methods known to a person skilled in the art, such as those described in the examples.

Stage e is generally carried out in an inert solvent, such as a 1-4C aliphatic alcohol, for example methanol, in the presence of sodium acetate at a
20 temperature of between 20°C and the boiling temperature of the reaction medium.

Stage f is carried out in an inert solvent, such as a chlorinated solvent (for example dichloromethane or dichloroethane), in the presence of
25 a reducing agent, such as sodium triacetoxyborohydride, at a temperature of between 0°C and 70°C .

The compounds of formula (I) for which R represents a CR_1R_2 radical in which R_1 represents a cyano, $-\text{S-alk-NR}_{16}\text{R}_{17}$, alkyl or $-\text{NR}_{20}\text{R}_{21}$ radical and R_2
30 represents a $-\text{C}(\text{R}_8)(\text{R}_{11})(\text{R}_{12})$ radical in which R_8 is a hydrogen atom can be prepared according to the following reaction scheme:



In these formulae, R_3 , R_4 , R_{11} , R_{12} , R_{15} , R_{16} and R_{17} have the same meanings as in the formula (I), alk represents an alkyl radical, Hal represents a halogen atom and M represents a metal and preferably copper.

Stage a is preferably carried out in a polar solvent, such as dimethyl sulphoxide, at a temperature of between 20 to 50°C.

Stage b is preferably carried out in an inert solvent, such as dimethyl sulphoxide, tetrahydrofuran or acetonitrile, in the presence of a base, such as an alkali metal carbonate (for example potassium carbonate) or ammonium hydroxide, at a temperature of between 20°C and the boiling temperature of the reaction medium.

Stage c is preferably carried out in an inert solvent, such as dimethyl sulphoxide, tetrahydrofuran or acetonitrile, in the presence of a base, such as an alkali metal carbonate (for example potassium carbonate) or ammonium hydroxide, at a temperature of between 20°C and the boiling point of the reaction medium.

Stage d is preferably carried out in an inert solvent, such as an ether (ethyl ether) or tetrahydrofuran, at a temperature of between -78°C and 20°C.

Stage e is preferably carried out in an inert solvent, such as dimethyl sulphoxide, tetrahydrofuran, acetonitrile, dichloromethane or dichloroethane, in the presence of a base, such as an alkali metal carbonate (for example potassium carbonate) or ammonium hydroxide, at a temperature of between 20°C and the boiling temperature of the reaction medium.

The compounds of formula (I) for which R represents a CR₁R₂ radical in which R₁ represents a -NR₁₈R₁₉ radical and R₁₈ and R₁₉ represent a hydrogen atom can be prepared by reduction of a corresponding compound of (I) for which R represents a CR₁R₂ radical in which R₁ represents a cyano radical.

This reaction is generally carried out in an inert solvent, such as tetrahydrofuran, ethyl ether or toluene, at a temperature of between 0°C and the boiling temperature of the reaction medium, in the presence of a reducing agent, such as aluminium hydride.

The compounds of formula (I) for which R represents a CR₁R₂ radical in which R₁ represents an -alk-NR₁₈R₁₉ radical, R₁₈ represents the hydrogen atom and R₁₉ represents an alkyl, cycloalkyl, cycloalkylalkyl, cycloalkylcarbonyl, -SO₂alk, -CO-NHalk or -COOalk radical can be prepared by reaction of a halide HalR₁₉, Hal represents a halogen, with a compound

of formula (I) for which R represents a CR₁R₂ radical in which R₁ represents an -alk-NR₁₈R₁₉ radical and R₁₈ and R₁₉ represent a hydrogen atom.

This reaction is carried out in an inert

5 polar solvent, such as acetonitrile, tetrahydrofuran or dimethylformamide, in the presence of an organic or inorganic base (alkali metal carbonate (for example sodium or potassium carbonate) or trialkylamine (for example triethylamine or dimethylaminopyridine)) at a

10 temperature of between 0°C and the boiling temperature of the solvent, optionally in the presence of palladium or of one of its salts or complexes.

The compounds of formula (I) for which R represents a CR₁R₂ radical in which R₁ represents an -alk-NR₁₈R₁₉ radical, R₁₈ represents an alkyl radical and R₁₉ represents an alkyl, cycloalkyl, cycloalkylalkyl, cycloalkylcarbonyl, -SO₂alk, -CO-NHalk or -COOalk radical can be prepared by reaction of an alkyl halide with a compound of formula (I) for which R represents a

20 CR₁R₂ radical in which R₁ represents an -alk-NR₁₈R₁₉ radical, R₁₈ represents a hydrogen atom and R₁₉ represents an alkyl, cycloalkyl, cycloalkylalkyl, cycloalkylcarbonyl, -SO₂alk, -CO-NHalk or -COOalk radical.

25 This reaction is carried out in an inert polar solvent, such as acetonitrile, tetrahydrofuran or dimethylformamide, in the presence of an organic or inorganic base (alkali metal carbonate (for example sodium potassium carbonate) or trialkylamine (for example triethylamine or dimethylaminopyridine)) at a

30 temperature of between 0°C and the boiling temperature of the solvent, optionally in the presence of palladium or of one of its salts or complexes.


The compounds of formula (I) for which R represents a CR₁R₂ radical in which either R₁ represents a hydrogen atom and R₂ represents a -C(R₈)(R₉)(R₁₀) or -C(R₈)(R₁₁)(R₁₂) radical or R₁ represents an alkyl,

NH-R₁₅, cyano, -S-alk-NR₁₆R₁₇, -alk-NR₁₈R₁₉ or -NR₂₀R₂₁ radical and R₂ represents a -C(R₈)(R₁₁)(R₁₂) radical and R₈ represents an alkyl radical can be prepared by alkylation of a corresponding compound of formula (I)

5 for which R₈ is a hydrogen atom.

This reaction is preferably carried out by means of a base, such as an alkali metal hydride (for example sodium hydride), an alkali metal amide (for example sodium amide) or an organometallic derivative, 10 in an inert solvent, such as an aliphatic ether (ethyl ether) or tetrahydrofuran, at a temperature of between -78°C and 30°C by means of an alkylating agent, such as an alkyl halide or an alkyl sulphonate.

The compounds of formula (I) for which R 15 represents a C=C(R₇)SO₂alk radical can also be prepared according to the following reaction scheme:




In these formulae, R₃, R₄ and R₇ have the same meanings as in the formula (I), alk represent an alkyl radical and Hal represents a halogen atom.

The reaction A is generally carried out in an inert solvent, such as an ether (for example ethyl ether), in the presence of a strong base, such as tert-butyllithium or n-butyllithium, at a temperature of 5 between -70°C and -50°C, followed by addition of sulphur and then of an alkyl halide (for example iodide or bromide).

The reaction B is generally carried out in an inert solvent, such as an ether (for example tetrahydrofuran), in the presence of a strong base, such as tert-butyllithium or n-butyllithium, at a temperature of between -70°C and -50°C, followed by addition of the azetidin-3-one, return to ambient temperature and hydrolysis.

15 The reaction C is carried out by any known method which makes it possible to oxidize a sulphur derivative without affecting the remainder of the molecule, such as those described above.

20 The compounds of formula (I) for which R represents a CHR_{33} radical and R_{33} represents an $-\text{NHCOR}_{34}$ radical can be prepared according to the following reaction scheme:



25 In these formulae, R_3 , R_4 and R_{34} have the same meanings as in the formula (I).

Stage a is generally carried out in an inert solvent, such as tetrahydrofuran, dioxane or a chlorinated solvent (for example dichloromethane or chloroform), at a temperature of between 15°C and 30°C

5 in the presence of a base, such as a trialkylamine (for example triethylamine or dipropylethylamine), or in pyridine at a temperature of between 0°C and 30°C.


Stage b is preferably carried out in methanol, in an autoclave, at a temperature of between 10 50 and 70°C.

Stage c is generally carried out in the presence of a coupling agent used in peptide chemistry, such as a carbodiimide (for example 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide or 15 N,N'-dicyclohexylcarbodiimide) or N,N'-carbonyldiimidazole, in an inert solvent, such as an ether (for example tetrahydrofuran or dioxane), an amide (dimethylformamide) or a chlorinated solvent (for example methylene chloride, 1,2-dichloroethane or 20 chloroform), at a temperature of between 0°C and the boiling temperature of the reaction mixture. Use may also be made of a reactive derivative of the acid, such as an acid chloride, optionally in the presence of an acid acceptor, such as a nitrogenous organic base (for 25 example trialkylamine, pyridine, 1,8-diazabicyclo-[5.4.0]undec-7-ene or 1,5-diazabicyclo[4.3.0]non-5-ene), in a solvent such as mentioned above, or a mixture of these solvents, at a temperature of between 0°C and the boiling temperature of the reaction 30 mixture.

The $R_{34}COOH$ derivatives are commercially available or can be obtained according to the methods described in R.C. Larock, Comprehensive Organic Transformations, VCH editor.

35 The compounds of formula (I) for which R represents a CHR_{33} radical and R_{33} represents an

$-\text{N}(\text{R}_{35})-\text{Y}-\text{R}_{36}$ radical can be prepared according to the following reaction scheme:



5 In these formulae, Y, R_4 , R_3 and R_{36} R_{35} have the same meanings as in the formula (I) and Hal represents a halogen atom and preferably an iodine, chlorine or bromine atom.


10 Stage a is generally carried out in an inert solvent, such as tetrahydrofuran, dioxane or a chlorinated solvent (for example dichloromethane or chloroform), in the presence of an amine, such as a trialkylamine (for example triethylamine), at a temperature of between 5°C and 20°C.

15 Stage b is generally carried out in an inert solvent, such as tetrahydrofuran, in the presence of sodium hydride at a temperature 0°C and the boiling temperature of the reaction medium.

20 The $\text{Hal}-\text{SO}_2\text{R}_{36}$ derivatives are commercially available or can be obtained by halogenation of the corresponding sulphonic acids, in particular in situ in the presence of chlorosulphonyl isocyanate and of alcohol, in an halogenated solvent (for example dichloromethane or chloroform).

The Hal-CO-R₃₆ derivatives are commercially available or can be prepared according to the methods described in R.C. Larock, Comprehensive Organic Transformations, VCH editor.

5 The compounds of formula (I) can also be prepared according to the following reaction scheme:



10 In these formulae, R_{34} , R_4 and R_3 have the same meanings as in the formula (I) and Ph represents a phenyl.

15 Stage a is generally carried out in an alcohol, such as methanol, in the presence of sodium borohydride at a temperature in the region of 20°C.

In stage b, the magnesium product from the bromine derivative is prepared and is reacted in an inert solvent, such as ethyl ether or tetrahydrofuran, at a temperature of between 0°C and the boiling 20 temperature of the reaction medium.

Stage c is carried out by means of a halogenating agent, such as hydrobromic acid, thionyl bromide, thionyl chloride or a mixture of triphenylphosphine and of carbon tetrabromide or 5 tetrachloride, in acetic acid or an inert solvent, such as dichloromethane, chloroform, carbon tetrachloride or toluene, at a temperature of between 0°C and the boiling temperature of the reaction medium.

Stage d is carried out by means of hydrogen 10 in the presence of palladium-charcoal in an alcohol, such as methanol, at a temperature in the region of 20°C.

Stage e is carried out in an inert solvent, such as acetonitrile, in the presence of an alkali 15 metal carbonate (for example potassium carbonate) and of potassium iodide at a temperature of between 20°C and the boiling temperature of the reaction medium.

The R_3Br derivatives and the R_4-CHO derivatives are commercially available or can be 20 obtained according to the methods described, for example, by R.C. Larock, Comprehensive Organic Transformations, VCH editor.

The compounds of formula (I) for which R represents a CHR_{33} radical and R_{33} represents an 25 $-N(R_{35})-Y-R_{36}$ radical in which R_{36} is a phenyl radical substituted by hydroxyl can also be prepared by hydrolysis of a corresponding compound of formula (I) for which R_{33} represents an $-N(R_{35})-Y-R_{36}$ radical in which R_{36} is a phenyl radical substituted by alkoxy.

30 This hydrolysis is generally carried out in an inert solvent, such as a chlorinated solvent (for example dichloromethane or chloroform), by means of boron tribromide at a temperature in the region of 20°C.

35 The compounds of formula (I) for which R represents a CHR_{33} radical and R_{33} represents an $-N(R_{35})-Y-R_{36}$ radical in which R_{36} is a phenyl radical


substituted by hydroxy(1C)alkyl can also be prepared by the action of diisobutylaluminium hydride on a corresponding compound of formula (I) for which R₃₃ represents an -N(R₃₅)-Y-R₃₆ radical in which R₃₆ is a 5 phenyl radical substituted by alkoxycarbonyl.

This reaction is generally carried out in an inert solvent, such as toluene, by means of diisopropylaluminium hydride at a temperature of between -50°C and 25°C.

10 The compounds of formula (I) for which R represents a CHR₃₃ radical and R₃₃ represents an -N(R₃₅)-Y-R₃₆ radical in which R₃₆ is a phenyl radical substituted by 1-pyrrolidinyl can also be prepared by reaction of pyrrolidine and of a corresponding compound 15 of formula (I) for which R₃₃ represents an -N(R₃₅)-Y-R₃₆ radical in which R₃₆ is a phenyl radical substituted by fluorine.

This reaction is preferably carried out in an inert solvent, such as dimethyl sulfoxide, at a 20 temperature of 90°C.

The compounds of formula (I) for which R represents a CHR₄₆ radical and R₄₆ represents an -N(R₄₇)R₄₈ in which R₄₈ is a hydrogen atom, -N(R₄₇)-CO-R₄₈ or -N(R₄₇)-SO₂R₄₉ radical, R₄₇ is a -C(R₅₄)(R₅₅)-Ar₃ or 25 -C(R₅₄)(R₅₅)-Het₃ radical and R₅₅ is a hydrogen atom can be prepared according to the following reaction scheme:



In these formulae, R_4 , R_3 , R_{49} and R_{54} have the same meanings as in the formula (I), Rb represents Ar_3 or Het_3 radical, Ar_3 and Het_3 having the same meanings

5 as in the formula (I), and Hal represents a halogen atom and preferably chlorine or bromine.

Stage a is generally carried out in an inert solvent, such as tetrahydrofuran, dioxane or a chlorinated solvent (for example dichloromethane or 10 chloroform), at a temperature of between 15 and 30°C in the presence of a base, such as a trialkylamine (for example triethylamine or dipropylethylamine), or in pyridine at a temperature between 0 and 30°C.

Stage b is preferably carried out in 15 methanol, in an autoclave, at a temperature of between 50 and 70°C.

Stage c is generally carried out in an inert solvent, such as a chlorinated solvent (for example dichloromethane), in the presence of sodium triacetoxyborohydride and acetic acid at a temperature 5 in the region of 20°C.


Stages d and e are generally carried out in an inert solvent, such as tetrahydrofuran, dioxane or a chlorinated solvent (for example dichloromethane or chloroform), in the presence of an amine, such as a 10 trialkylamine (for example triethylamine), at a temperature of between 5°C and 20°C.

The Rb-COR₅₄ derivatives are commercially available or can be obtained according to the methods described, for example, by R.C. Larock, *Comprehensive 15 Organic Transformations*, VCH editor.

The Hal-SO₂R₄₉ derivatives are commercially available or can be obtained by halogenation of the corresponding sulphonic acids, in particular in situ in the presence of chlorosulphonyl isocyanate and of 20 alcohol, in a halogenated solvent (for example dichloromethane or chloroform).

These Hal-COR₄₈ derivatives are commercially available or can be prepared by halogenation of the corresponding carboxylic acids, in particular in situ 25 in the presence of thionyl chloride, in an halogenated solvent (for example dichloromethane or chloroform).

The compounds of formula (I) for which R represents a CHR₄₆ radical and R₄₆ represents an -N(R₄₇)R₄₈ radical can be prepared according to the 30 following reaction scheme:




In these formulae, R_4 , R_3 , R_{47} and R_{48} have the same meanings as in the formula (I).

This reaction is generally carried out in an 5 inert solvent, such as a chlorinated solvent (for example dichloromethane), in the presence of sodium triacetoxyborohydride and of acetic acid at a temperature in the region of 20°C .

The compounds $\text{HN}(R_{47})R_{48}$ are commercially 10 available or can be prepared according to conventional methods known to a person skilled in the art or by application or adaptation of the methods described by Park K.K. et al., J. Org. Chem., 60 (19), 6202 (1995); Kalir A. et al., J. Med. Chem., 12 (3), 473 (1969); 15 Sarges R., J. Org. Chem., 40 (9), 1216 (1975); Zaugg H.E., J. Org. Chem., 33 (5), 2167 (1968); Med. Chem., 10, 128 (1967); J. Am. Chem. Soc., 2244 (1955); Chem. Ber., 106, 2890 (1973); Chem. Pharm. Bull., 16 (10), 1953 (1968); Bull. Soc. Chim. Fr., 835 (1962).

20 The azetidinones 3 can be obtained by oxidation of the corresponding azetidinols 2, preferably in dimethyl sulphoxide, by means of the sulphur trioxide-pyridine complex at a temperature in the region of 20°C or by means of dimethyl sulphoxide, 25 in the presence of oxalyl chloride and of triethylamine, at a temperature of between -70°C and -50°C .

The compounds of formula (I) for which R represents a CHR_{46} radical and R_{46} represents an 30 $-\text{N}(\text{R}_{47})\text{COR}_{48}$ or $-\text{N}(\text{R}_{47})\text{SO}_2\text{R}_{49}$ radical can be prepared according to the following reaction scheme:




In these formulae, R_4 , R_3 , R_{47} , R_{48} and R_{49} have the same meanings as in the formula (I) and Hal

5 represents a halogen atom and preferably chlorine.

Stages a and b are generally carried out in an inert solvent, such as tetrahydrofuran, dioxane or a chlorinated solvent (for example dichloromethane or chloroform), in the presence of an amine, such as a 10 trialkylamine (for example triethylamine), at a temperature of between 5°C and 20°C.

The compounds of formula (I) for which R represents a CHR_{46} radical and R_{46} represents an $-N(R_{47})-SO_2-R_{49}$ radical for which R_{47} is a Het_3 or Ar_3 15 radical can be prepared according to the following reaction scheme:



In these formulae, R_4 , R_3 and R_{49} have the same meanings as in the formula (I), Rd represents an Ar_3 or Het_3 radical (Het_3 and Ar_3 having the same meanings as 5 in the formula (I)) and Ms represents a methylsulphonyloxy radical.


Stage a is generally carried out in an inert solvent, such as tetrahydrofuran, in the presence of triphenylphosphine and of diethyl azodicarboxylate at a 10 temperature of between $0^\circ C$ and the boiling temperature of the reaction medium.

Stage b is generally carried out in an inert solvent, such as tetrahydrofuran, dioxane or a chlorinated solvent (for example dichloromethane or 15 chloroform), at a temperature of between $15^\circ C$ and $30^\circ C$ in the presence of a base, such as a trialkylamine (for example triethylamine or dipropylethylamine), or in pyridine at a temperature between $0^\circ C$ and $30^\circ C$.

Stage c is preferably carried out in an inert 20 solvent, such as dioxane, in the presence of $CsCO_3$, at reflux of the reaction mixture.

The derivatives for which Rd represents an N -oxidized nitrogenous heterocycle can be reduced to nonoxidized compound according to the method described 25 by Sanghanel E. et al., *Synthesis*, 1375 (1996).


The $Rd-NH-SO_2R_{49}$ derivatives can be obtained according to the following reaction scheme:



In these formulae, Hal represents a halogen atom and Rd represents a Het₃ or Ar₃ radical. The 5 reaction is carried out in an inert solvent, such as tetrahydrofuran, dioxane or a chlorinated solvent (for example dichloromethane or chloroform), at a temperature of between 15°C and 30°C in the presence of a base, such as a trialkylamine (for example 10 triethylamine or dipropylethylamine), or in pyridine at a temperature of between 0°C and 30°C.

The derivatives for which Rd represents an N-oxidized nitrogenous heterocycle can be obtained according to methods described by Rhie R., 15 Heterocycles, 41 (2), 323 (1995).

The compounds of formula (I) for which R represents a CHR₄₆ radical and R₄₆ represents an -N(R₄₇)-SO₂-R₄₉ radical for which R₄₇ is a piperid-4-yl radical optionally substituted on the nitrogen by an 20 alkyl radical can also be prepared according to the following reaction scheme:



In these formulae, R_4 , R_3 and R_{49} have the same meanings as in the formula (I), alk represents an alkyl radical and Re represents a tert-butylcarbonyloxy 5 radical.

Stage a is carried out in an inert solvent, such as a chlorinated solvent (for example dichloromethane), in the presence of a hydride, such as sodium triacetoxyborohydride, and acetic acid at a 10 temperature of between 0°C and the boiling temperature of the reaction medium.

Stage b is generally carried out in an inert solvent, such as tetrahydrofuran, dioxane or a chlorinated solvent (for example dichloromethane or 15 chloroform), in the presence of an amine, such as a trialkylamine (for example triethylamine), at a temperature of between 5°C and 20°C .

Stage c is carried out by means of hydrochloric acid in dioxane at a temperature of

between 0°C and the boiling temperature of the reaction medium.

Stage d is carried out by any means known to a person skilled in the art for alkylating an amine 5 without affecting the remainder of the molecule. Use may be made, for example, of an alkyl halide in the presence of an organic base, such as triethylamine, or an alkali metal hydroxide (for example sodium hydroxide or potassium hydroxide), optionally in the presence of 10 tetrabutylammonium bromide, in an inert solvent, such as dimethyl sulphoxide, dimethylformamide or pyridine, at a temperature of between 20 and 50°C.

The compounds of formula (I) for which R represents a CHR_{46} radical and R_{46} represents an 15 $-\text{N}(\text{R}_{47})-\text{SO}_2-\text{R}_{49}$ radical for which R_{47} is a phenyl radical substituted by a pyrrolid-1-yl radical can also be prepared by reaction of pyrrolidine with a corresponding compound of formula (I) for which R_{46} represents a $-\text{N}(\text{R}_{47})\text{SO}_2\text{R}_{49}$ radical for which R_{47} is a 20 phenyl radical substituted by a halogen atom.

This reaction is preferably carried out in dimethyl sulphoxide at a temperature of between 50 and 95°C.

It is understood for the person skilled in 25 the art that, in order to carry out the processes according to the invention described above, it may be necessary to introduce protective groups for the amino, hydroxyl and carboxyl functional groups in order to prevent side reactions. These groups are those which 30 make it possible to be removed without affecting the remainder of the molecule. Mention may be made, as examples of protective groups for the amino functional group, of tert-butyl or methyl carbamates, which can be regenerated by means of iodotrimethylsilane, or allyl 35 carbamates, by means of palladium catalysts. Mention may be made, as examples of protective groups for the hydroxyl functional group, of triethylsilyl and tert-

butyldimethylsilyl, which can be regenerated by means of tetrabutylammonium fluoride, or asymmetric acetals (for example methoxy methyl or tetrahydropyranyl), with regeneration by means of hydrochloric acid. Mention may

5 be made, as protective groups for the carboxyl functional groups, of esters (for example allyl or benzyl), oxazoles and 2-alkyl-1,3-oxazolines. Other protective groups which can be used are described by Greene T.W. et al., *Protecting Groups in Organic*

10 *Synthesis*, second edition, 1991, John Wiley & Sons.

The compounds of formula (I) can be purified by the usual known methods, for example by crystallization, chromatography or extraction.

The enantiomers or the compounds of formula

15 (I) can be obtained by resolution of the racemates, for example by chromatography on a chiral column according to Pirckle W.H. et al., *Asymmetric Synthesis*, vol. 1, Academic Press (1983), or by formation of salts or by synthesis from chiral precursors. The diastereoisomers

20 can be prepared according to known conventional methods (crystallization, chromatography or starting from chiral precursors).

Mention may be made, as examples of pharmaceutically acceptable salts of the following

25 salts: benzenesulphonate, hydrobromide, hydrochloride, citrate, ethanesulphonate, fumarate, gluconate, iodate, isethionate, maleate, methanesulphonate, methylenebis(β -oxynaphthoate), nitrate, oxalate, pamoate, phosphate, salicylate, succinate, sulphate,

30 tartate, theophyllineacetate and p-toluenesulphonate.

Example 1:

N-{1-[Bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-yl)methylsulphonamide can be prepared by

35 carrying out the preparation in the following way: 0.042 cm³ of phosphorus trichloride is run into a solution of 0.144 g of N-{1-[bis(4-chlorophenyl)-

methyl]azetidin-3-yl}-N-(1-oxidopyrid-3-yl)methylsulphonamide in 5 cm³ of chloroform and then the mixture is heated to the reflux temperature. After stirring for 1 hour 30 minutes, the reaction mixture is 5 allowed to return to normal temperature, 5 cm³ of 0.1N hydrochloric acid are then added to the mixture, and then the mixture is stirred and separated by settling. The organic phase is diluted with 20 cm³ of chloroform, dried over magnesium sulphate, filtered and then 10 concentrated to dryness under reduced pressure (2.7 kPa). The residue is chromatographed on a column of silica gel (particle size 0.063-0.200 mm, height 9 cm, diameter 1.8 cm), elution being carried out under a pressure of 0.1 bar of argon with a mixture of 15 dichloromethane and of methanol (95/5 by volume) and 15-cm³ fractions being collected. Fractions 2 to 4 are combined and concentrated to dryness under reduced pressure (2.7 kPa). The residue is stirred with 15 cm³ of diethyl ether, the suspension is filtered and the 20 solid is pulled dry and then dried under reduced pressure (2.7 kPa). 35 mg of N-[1-[bis(4-chlorophenyl)-methyl]azetidin-3-yl]-N-(pyrid-3-yl)methylsulphonamide are obtained in the form of a cream solid [¹H N.M.R. spectrum (300 MHz, CDCl₃, δ in ppm): from 2.80 to 2.95 25 (mt, 2H), 2.87 (s, 3H), 3.51 (split t, J = 7 and 1.5 Hz, 2H), 4.18 (s, 1H), 4.65 (mt, 1H), from 7.15 to 7.35 (mt, 8H), 7.37 (broad dd, J = 8 and 5 Hz, 1H), 7.64 (reduced d, J = 8 Hz, 1H), 8.52 (broad d, J = 2 Hz, 1H), 8.61 (broad d, J = 5 Hz, 1H)].

30

Example 2:

Method 1:

N-[1-[Bis(4-chlorophenyl)methyl]azetidin-3-yl]-N-(3,5-difluorophenyl)methylsulphonamide can be 35 prepared by carrying out the preparation in the following way: 1.0 g of cesium carbonate is added to a mixture of 1.23 g of 1-[bis(4-chlorophenyl)methyl]-

azetidin-3-yl} methylsulphonate and of 0.66 g of N-(3,5-difluorophenyl)methylsulphonamide in 25 cm³ of dioxane. After stirring for 5 hours at the reflux temperature and then for 20 hours at 20°C, 50 cm³ of

5 diethyl ether and 30 cm³ of brine are added to the reaction mixture and then the reaction mixture is stirred and separated by settling. The organic phase is dried over magnesium sulphate, filtered and then concentrated to dryness at 50°C under reduced pressure

10 (2.7 kPa). The orange oil obtained is chromatographed on a column of silica gel (particle size 0.040-0.063 mm, height 25 cm, diameter 2.0 cm), elution being carried out under a pressure of 0.5 bar of argon with a mixture of cyclohexane and of ethyl acetate (65/35 by

15 volume) and 10-cm³ fractions being collected. Fractions 6 to 10 are combined and concentrated to dryness under reduced pressure (2.7 kPa). The residue is chromatographed on a column of silica gel (particle size 0.040-0.063 mm, height 15 cm, diameter 1.0 cm),

20 elution being carried out under a pressure of 0.5 bar of argon with a mixture of cyclohexane and of ethyl acetate (65/35 by volume) and 5-cm³ fractions being collected. Fraction 7 is concentrated to dryness under reduced pressure (2.7 kPa). 0.11 g of

25 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulphonamide is obtained in the form of a white powder [¹H N.M.R. spectrum (300 MHz, CDCl₃, δ in ppm): 2.82 (s, 3H), 2.85 (mt, 2H), 3.52 (split t, J = 7 and 2 Hz, 2H), 4.22 (s, 1H), 4.47 (mt, 30 1H), from 6.75 to 6.90 (mt, 3H), from 7.20 to 7.35 (mt, 8H)].

Method 2:

0.78 cm³ of diethyl azodicarboxylate and

35 1.31 g of triphenylphosphine are added under argon to a solution of 1.41 g of 1-[bis(4-chlorophenyl)methyl]azetidin-3-ol and of 0.95 g of N-

(3,5-difluorophenyl)methylsulphonamide in 100 cm³ of anhydrous tetrahydrofuran. After stirring for 16 hours at 20°C, 300 cm³ of ethyl acetate are added and the reaction mixture is washed twice with 100 cm³ of water,

5 dried over magnesium sulphate and concentrated to dryness under reduced pressure (2.7 kPa). The residue is chromatographed on a column of silica gel (particle size 0.20-0.063 mm, height 50 cm, diameter 4 cm), elution being carried out under a pressure of 0.6 bar

10 of argon with a mixture of cyclohexane and of ethyl acetate (75/25 by volume) and 125-cm³ fractions being collected. Fractions 6 to 12 are combined and concentrated to dryness under reduced pressure (2.7 kPa). 1.8 g of a solid are obtained, which solid

15 is dissolved under hot conditions in an ethyl acetate/diisopropyl ether mixture (15/2 by volume), cooled and diluted with 100 cm³ of pentane to initiate crystallization. After filtration and drying, 1.0 g of

20 N-[1-[bis(4-chlorophenyl)methyl]azetidin-3-yl]-N-(3,5-difluorophenyl)methylsulphonamide is obtained in the form of white crystals melting at 154°C.

N-(3,5-Difluorophenyl)methylsulphonamide can be prepared by carrying out the preparation in the following way: 2.0 cm³ of methylsulphonyl chloride,

25 3.8 cm³ of triethylamine and 20 mg of 4-dimethylaminopyridine are slowly added to a solution of 3.5 g of 3,5-difluoroaniline in 75 cm³ of dichloromethane. After stirring for 20 hours at 20°C, the reaction mixture, to which 20 cm³ of dichloromethane

30 and 20 cm³ of water are added, is stirred and then separated by settling. The organic phase is dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa). The residue is chromatographed on a column of silica gel (particle size 0.063-0.200 mm, height 20 cm, diameter 2.0 cm), elution being carried out under a pressure of 0.1 bar of argon with dichloromethane and 25-cm³ fractions being

collected. Fractions 14 to 20 are combined and concentrated to dryness under reduced pressure (2.7 kPa). 0.66 g of N-(3,5-difluorophenyl)methyl-sulphonamide is obtained in the form of a white powder.

5 1-[Bis(4-chlorophenyl)methyl]azetidin-3-yl methylsulphonate can be prepared by carrying out the preparation in the following way: 3.5 cm³ of methylsulphonyl chloride are added under argon over 10 minutes to a solution of 12 g of 1-[bis(4-chlorophenyl)methyl]azetidin-3-ol in 200 cm³ of dichloromethane, then the mixture is cooled to +5°C and 3.8 cm³ of pyridine are run in over 10 minutes. After stirring for 30 minutes at +5°C and then for 20 hours at 20°C, the reaction mixture is diluted with 100 cm³ of water and 100 cm³ of dichloromethane. The mixture, 10 filtered first, is separated by settling. The organic phase is washed with water and then dried over magnesium sulphate, filtered and concentrated to dryness under reduced pressure (2.7 kPa). The oil 15 obtained is chromatographed on a column of silica gel (particle size 0.063-0.200 mm, height 40 cm, diameter 3.0 cm), elution being carried out under a pressure of 0.5 bar of argon with a mixture of cyclohexane and of ethyl acetate (70/30 by volume) and 20 100-cm³ fractions being collected. Fractions 4 to 15 are combined and concentrated to dryness under reduced pressure (2.7 kPa). 6.8 g of 1-[bis(4-chlorophenyl)-methyl]azetidin-3-yl methylsulphonate are obtained in 25 the form of a yellow oil.

30 1-[Bis(4-chlorophenyl)methyl]azetidin-3-ol can be prepared according to the procedure described by Katritzky A.R. et al., J. Heterocycl. Chem., 271 (1994), starting from 35.5 g of [bis(4-chlorophenyl)-methyl]amine hydrochloride and 11.0 cm³ of 35 epichlorohydrin. 9.0 g of 1-[bis(4-chlorophenyl)-methyl]azetidin-3-ol are isolated.

[Bis(4-chlorophenyl)methyl]amine hydrochloride can be prepared according to the method described by Grisar M. et al., J. Med. Chem., 885 (1973).

5 The synergistic effect of the combination of one or more products which activate dopaminergic neurotransmission in the brain and of one or more CB1 antagonists in the treatment of Parkinson's disease was determined in a model of akinesia induced by reserpine
10 10 in the rat according to the following protocol:

Male Sprague-Dawley rats were treated with reserpine administered subcutaneously at a dose of 3 mg/kg (1 ml/kg) in order to induce akinesia in the animal. 18 hours after this treatment, the locomotor
15 activity of these animals was measured and recorded using an automatic system (Videotrack, France). The locomotion, expressed in centimetres, is estimated by a mean overall distance covered during this period (n = 11-38 rats per group). The statistical analysis is
20 carried out by variance analysis and a post-hoc comparison (if appropriate) using a Mann-Whitney or Dunnett test. A significant effect is recorded for p<0.05.

The synergistic effect of the combination is
25 demonstrated in Tables 1 and 2.

Table 1 relates to the ip administration of the CB1 antagonist and Table 2 relates to the po administration of the CB1 antagonist.

The results for the ip administration of the
30 CB1 antagonist (Table 1) are expressed as percentage of increase with respect to the activity of quinpirole and as percentage of decrease with respect to the activity of a very strong dose of levodopa.

The combination of a CB1 receptor antagonist
35 and of a D2 dopaminergic agonist (quinpirole) is produced in the following way:

The CB1 antagonist product (1.5 mg/kg i.p., 2 ml/kg) and quinpirole (62.5 µg/kg i.p., 1 ml/kg) are coadministered 18 hours after the injection of reserpine. The recording of the motor activity begins 5 minutes after the co-administration of the products and lasts 1 hour.

The combination of the CB1 receptor antagonist and of a strong dose of levodopa (dyskinesia model) is produced in the following way:

10 The CB1 antagonist product (3 mg/kg i.p., 2 ml/kg) and levodopa (120 mg/kg + benserazide, 50 mg/kg i.p., 5 ml/kg) are co-administered. Benserazide is a peripheral dopa-decarboxylase inhibitor which allows levodopa to cross the

15 hematoencephalic barrier before its conversion into dopamine. The recording of the motor activity begins 5 minutes after the co-administration and lasts 2.5 hours.

20

TABLE 1

Reserpine-treated rats	Combination with quinpirole (62.5 µg/kg ip)	Combination with levodopa (120 mg/kg ip)
Example 2	+139%*** (1.5 mg/kg i.p.)	-54% NS (3 mg/kg i.p.)
Example 1	+96%**	-20% NS (1.5 mg/kg) (3 mg/kg untested)
SR141716A 1 mg/kg i.p.	+116%***	-61%*

SR141716A: N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride

25 ANOVA + Mann-Whitney: *p<0.05, **p<0.01, ***p<0.001.

These results according to the invention show that the CB1 receptor antagonists:

- significantly potentiate the effects of a D2 dopaminergic agonist (reduction in the symptoms of Parkinson's disease)
- and reduce the hyperactivity induced by a very strong dose of levodopa (antidyskinetic activity).

5

The studies by the oral route are carried out in a hydrophobic formulation solvent Labrafil/Labrasol (40/60%, w/w). These products are administered (in a volume of 1 ml/kg) one hour before the dopaminergic 10 agonist. The recording of the locomotor activity begins 5 min after the intraperitoneal injection of the dopaminergic agonist and lasts 1 hour. The D1 dopaminergic agonist is 0.3 mg/kg C1-APB. The D2 dopaminergic agonist is 0.1 mg/kg quinpirole.

15 The results for the po administration of the CB1 antagonist at three different doses (1, 3 and 10 mg/kg/po) and the results (Table 2) are expressed as percentage of increase with respect to the activity of quinpirole and a percentage of decrease with respect to 20 the activity of a strong dose of C1-APB (SKF 82958).

TABLE 2

	Dose mg/kg po	Combination with quinpirole (0.1 mg/kg ip)	Combination with C1- APB (0.3 mg/kg ip)
Example 2	1	+55% NS	-16% NS
	3	+62%*	-61%*
	10	+97%**	-62%*
Example 1	1	-1% NS	+22% NS
	3	+101%*	-21% NS
	10	+102%*	-53%*
SR141716A	1	+57%* NS	-32% NS
	3	+121%**	-58%*
	10	+87%**	-82%**

SR141716A: N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride

ANOVA + Dunnett: *p<0.05, **p<0.01

5 These results according to the invention show that the CB1 receptor antagonists:

- significantly potentiate the effects of a D2 dopaminergic agonist (reduction in the symptoms of Parkinson's disease)
- 10 - and reduce the hyperactivity induced by a strong dose of D1 type (antidyskinetic activity).

The compounds of the combination can be employed orally, parenterally, transdermally or rectally, either simultaneously or separately or spread 15 out over time.

The present invention also relates to the pharmaceutical compositions comprising the combination of one or more products which activate neurotransmission in the brain and of one or more CB1 20 receptor antagonists as defined above with a pharmaceutically acceptable vehicle.

Use may be made, as solid compositions for oral administration, of tablets, pills, powders (hard gelatin capsules, cachets) or granules. In these

25 compositions, the active principles are mixed with one or more inert diluents, such as starch, cellulose, sucrose, lactose or silica, under an argon stream. These compositions can also comprise substances other than the diluents, for example one or more lubricants, 30 such as magnesium stearate or talc, a colorant, a coating (dragées) or a glaze.

Use may be made, as liquid compositions for oral administration, of pharmaceutically acceptable solutions, suspensions, emulsions, syrups and elixirs 35 comprising inert diluents, such as water, ethanol, glycerol, vegetable oils or liquid paraffin. These compositions can comprise substances other than the

diluents, for example wetting, sweetening, thickening, flavouring or stabilizing products.

The sterile compositions for parenteral administration can preferably be solutions in aqueous 5 or nonaqueous form, suspensions or emulsions. Use may be made, as solvent or vehicle, of water, propylene glycol, a polyethylene glycol, vegetable oils, in particular olive oil, injectable organic esters, for example ethyl oleate, or other suitable organic 10 solvents. These compositions can also comprise adjuvants, in particular wetting, isotonizing, emulsifying, dispersing and stabilizing agents. Sterilization can be carried out in several ways, for example by aseptic filtration, by incorporating 15 sterilizing agents in the composition, by irradiation or by heating. They can also be prepared in the form of sterile solid compositions which can be dissolved at the time of use in sterile water or any other injectable sterile medium.

20 The compositions for rectal administration are suppositories or rectal capsules which comprise, in addition to the active product, excipients such as cocoa butter, semisynthetic glycerides or polyethylene glycols.

25 The pharmaceutical compositions including the combination as defined above generally comprise 0.1 to 500 mg of the CB1 antagonist. The present invention also relates to the method for the treatment of Parkinson's disease which consists in administering, to 30 the patient, a combination or a pharmaceutical composition including the combination as defined above, either simultaneously or separately or spread out over time.

35 The doses depend on the desired effect, on the duration of treatment and on the administration route used; they are generally from 0.1 to 500 mg of

the CB1 antagonist per day by the oral route for an adult.

Generally, the doctor will determine the appropriate dosage according to the age, weight and any 5 other factors specific to the subject to be treated.

2002337277 22 May 2008

80

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A kit characterised by a combination of one or more products which activate dopaminergic neurotransmission in the brain and of one or more azetidine derivatives chosen from the following compounds:
 - 5 N-[1-[bis(4-chlorophenyl)methyl]azetidin-3-yl]-N-(pyrid-3-yl)methylsulphonamide,
N-[1-[bis(4-chlorophenyl)methyl]azetidin-3-yl]-N-(3,5-difluorophenyl)methylsulphonamide,
their pharmaceutically acceptable salts;
 - 10 wherein said kit is so configured to ensure mixing on use of said one or more products and of said one or more azetidine derivatives or their pharmaceutically acceptable salts
2. A kit characterised by a combination of one or more products which activate dopaminergic neurotransmission in the brain and of one azetidine derivative:
 - 15 N-[1-[bis(4-chlorophenyl)methyl]azetidin-3-yl]-N-(pyrid-3-yl)methylsulphonamide,
their pharmaceutically acceptable salts;
wherein said kit is so configured to ensure mixing on use of said one or more products and of said one azetidine derivative or their pharmaceutically acceptable salts
 - 20 3. A kit characterised by a combination of one or more products which activate dopaminergic neurotransmission in the brain and of one azetidine derivative:
 - 25 N-[1-[bis(4-chlorophenyl)methyl]azetidin-3-yl]-N-(3,5-difluorophenyl)methylsulphonamide,
their pharmaceutically acceptable salts;

2002337277 22 May 2008

81

wherein said kit is so configured to ensure mixing on use of said one or more products and of said one azetidine derivative or their pharmaceutically acceptable salts

4. Kit according to any one of Claims 1 to 3, characterised in that the product
5 which activates dopaminergic neurotransmission in the brain is chosen from the following compounds:

10 bromocriptine, cabergoline, adroglide, BAM-1110, duodopa, levodopa, dopadose, CHF1512, PNU-95666, ropinirole, pramipexole, rotigotine, spheramine, TV1203, uridine, rasagiline, selegiline, SL340026, tolcapone and entacapone.

5. Kit according to any one of Claims 1 to 3, characterised in that the product which activates dopaminergic neurotransmission in the brain is levodopa and the CB1 antagonist is N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-yl)methylsulphonamide.

15 6. Kit according to any one of Claims 1 to 3, characterised in that the product which activates dopaminergic neurotransmission in the brain is levodopa and the azetidine derivative is N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl) methylsulphonamide.

7. Kit according to any one of Claims 1 to 6 for its application as medicament.

20 8. Kit according to any one of Claims 1 to 6 for its application as medicament in the treatment of Parkinson's disease.

9. Pharmaceutical composition comprising one or more products activating dopaminergic neurotransmission in the brain and one or more azetidine derivatives chosen from the following compounds:

25 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-yl)methylsulphonamide,

2002337277 22 May 2008

82

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulphonamide,

with a compatible and pharmacologically acceptable vehicle.

10. Pharmaceutical composition comprising one or more products activating
5 dopaminergic neurotransmission in the brain and an azetidine derivative:

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-yl)methylsulphonamide,

with a compatible and pharmaceutically acceptable vehicle.

11. Pharmaceutical composition comprising one or more products activating
10 dopaminergic neurotransmission in the brain and an azetidine derivative:

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulphonamide,

with a compatible and pharmaceutically acceptable vehicle.

12. Pharmaceutical composition according to any one of Claims 9 to 11,
15 characterised in that the product which activates dopaminergic neurotransmission
in the brain is chosen from the following compounds:

bromocriptine, cabergoline, talipexole, adrogolide, BAM-1110, duodopa,
levodopa, dopadose, CHF1301, CHF1512, PNU-95666, ropinirole, pramipexole,
rotigotine, spheramine, TV1203, uridine, rasagiline, selegiline, SL340026,
20 tolcapone and entacapone.

13. Pharmaceutical composition according to Claim 10, characterised in that
the product which activates dopaminergic neurotransmission in the brain is
levodopa and the azetidine derivative is

25 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-yl)methylsulphonamide.

14. Pharmaceutical composition according to Claim 11, characterized in that
the product which activates dopaminergic neurotransmission in the brain is
levodopa and the azetidine derivative is N-{1-[bis(4-chlorophenyl)methyl]azetidin-
3-yl}-N-(3,5-difluorophenyl)methylsulphonamide.

2002337277 22 May 2008

83

15. Pharmaceutical composition according to any one of Claims 9 to 14, comprising from 0.1 to 500 mg of azetidine derivative

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(pyrid-3-yl)methylsulphonamide.

5 16. Pharmaceutical composition according to any one of Claims 9 to 14, comprising from 0.1 to 500 mg of azetidine derivative

N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulphonamide

10 17. A method of treating Parkinson's disease, which method includes administering to a patient a therapeutically effective amount of a pharmaceutical composition according to any one of Claims 9 to 16.

18. Use of a pharmaceutical composition according to any one of Claims 9 to 16 in the manufacture of a medicament in the treatment of Parkinson's disease.

15

AVENTIS PHARMA S.A.

WATERMARK PATENT & TRADE MARK ATTORNEYS

P23721AU00